OxPhos Dysfunction Causes Hypermetabolism and Reduces Lifespan in Cells and in Patients with Mitochondrial Diseases

Gabriel Sturm[1], Kalpita R Karan[1], Anna Monzel[1], Balaji S Santhanam[2], Tanja Taivassalo[3], Céline Bris[4,5], Sarah A Duplaga[6], Marissa Cross[1], Atif Towheed[1,7], Albert Higgins-Chen[8], Meagan J McManus[9,10], Andres Cardenas[11], Jue Lin[12], Elissa S Epel[13], Shamima Rahman[14], John Vissing[15], Bruno Grassi[16], Morgan Levine[17], Steve Horvath[18], Ronald G Haller[19], Guy Lanaers[4,5], Douglas C Wallace[10], Saeed Tavazoie[2], Vincent Procaccio[4,5], Brett A Kaufman[6], Erin L Seifert[21], Michio Hirano[22], Martin Picard[1,22,23,*]

[1] Department of Psychiatry, Division of Behavioral Medicine, Columbia University Irving Medical Center, New York, NY, United States

[2] Departments of Biological Sciences, Systems Biology, and Biochemistry and Molecular Biophysics, Institute for Cancer Dynamics, Columbia University, New York, United States

[3] Department of Physiology and Functional Genomics, Clinical and Translational Research Building, University of Florida, Gainesville, FL, United states

[4] Department of Genetics, Angers Hospital, Angers, France

[5] Angers University, MitoLab team, UMR CNRS 6015 - INSERM U1083, MitoVasc Institute, Angers, France

[6] Department of Medicine, Vascular Medicine Institute and Center for Metabolic and Mitochondrial Medicine, University of Pittsburgh, Pittsburgh, PA, United States

[7] Touro College of Osteopathic Medicine, Middletown, NY, United States

[8] Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA

[9] Department of Anesthesiology and Critical Care Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, United States

[10] Center for Mitochondrial and Epigenomic Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, United States

[11] Department of Environmental Health Sciences and Center for Computational Biology, University of California Berkeley, Berkeley, CA, United States

[12] Department of Biochemistry and Biophysics, University of California, San Francisco, CA, United States

[13] Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, United States

[14] Mitochondrial Research Group, UCL Great Ormond Street Institute of Child Health, and Metabolic Unit, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

[15] Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

[16] Department of Medicine, University of Udine, Udine, Italy

[17] Department of Pathology, Yale University School of Medicine, New Haven, CT, United States

[18] Human Genetics, David Geffen School of Medicine, University of California, Los Angeles CA, United States

[19] Neuromuscular Center, Institute for Exercise and Environmental Medicine of Texas Health Resources and Department of Neurology, University of Texas Southwestern Medical Center, United States

[21] Thomas Jefferson University, Department of Pathology, Anatomy and Cell Biology and MitoCare Center, Philadelphia, PA, United States

[22] Department of Neurology, H. Houston Merritt Center, Columbia Translational Neuroscience Initiative, Columbia University Irving Medical Center, New York, NY, United States

[23] New York State Psychiatric Institute, New York, NY, United States

* *Correspondence*: martin.picard@columbia.edu

Abstract

Patients with primary mitochondrial diseases present with fatigue and multi-system disease, are often lean, and die prematurely, but the mechanistic basis for this clinical picture remains unclear. Integrating data from 17 cohorts of patients with mitochondrial diseases (n=690), we find that clinical mitochondrial disorders increase resting energy expenditure, a state termed *hypermetabolism*. In a longitudinal cellular model of primary patient-derived fibroblasts from multiple donors, we show that genetic and pharmacological disruptions of oxidative phosphorylation (OxPhos) similarly trigger increased energy consumption in a cell-autonomous manner, despite near-normal OxPhos coupling efficiency. Hypermetabolism was associated with mtDNA instability, activation of the integrated stress response, increased extracellular secretion of age-related cytokines and metabokines including GDF15, as well as an accelerated rate of telomere erosion and epigenetic aging, and a reduced Hayflick limit. Finally, we generate a longitudinal RNASeq and DNA methylation resource dataset, which reveals conserved, energetically demanding, genome-wide recalibrations to OxPhos dysfunction. Hypermetabolism, or the increased energetic cost of living in mitochondrial diseases, has important biological and clinical implications.

Keywords: mitochondrial disorders, longitudinal, energy expenditure, epigenetics, GDF15, cell-free mitochondrial DNA

Introduction

Mitochondrial diseases are caused by mutations in either the mitochondrial (mtDNA) or nuclear (nDNA) genomes, which impair oxidative phosphorylation (OxPhos) and the ability to convert food substrates into ATP [1]. However, cellular dysfunction arises even when ATP levels are normal [2-4], suggesting that energy deficiency may not be the primary disease initiator. In animal models of mitochondrial disease, OxPhos defects trigger nuclear transcriptional responses, including the integrated stress response (ISR) [3,5-8], and downstream gene products such as growth differentiation factor 15 (GDF15) are secreted systemically where they impact metabolic functions [9,10]. This implicates conserved systemic signaling pathways in the pathogenesis of mitochondrial disease [11]. Considering that these stress pathways entail fundamentally energetically-demanding cellular processes, OxPhos defects could therefore increase energy consumption at the cellular and organismal levels. However, the metabolic costs of cellular and systemic recalibrations in mitochondrial disorders have not been defined. Here we examine this question in clinical datasets and in two *in vitro* models.

Clinically, OxPhos dysfunction causes a broad spectrum of multi-system disorders where symptoms include, among others, fatigue and exercise intolerance [12,13]. As a result, most patients with mitochondrial diseases curtail physical activity and exercise [14,15]. The reduced mitochondrial capacity to oxidize substrates[16] coupled to minimal physical activity levels would be expected to promote positive energy balance and body fat accumulation, leading to obesity. However, patients with mitochondrial diseases are rarely obese. In fact, patients with moderate to severe disease on average classify as underweight [17]. Although gastro-intestinal symptoms that limit food intake or absorption could contribute to this phenotype, the rarity of obesity in mitochondrial disease remains a clinical paradox. However, this may be resolved by the counterintuitive notion that mitochondrial OxPhos dysfunction may not decrease energy consumption and expenditure, but may rather *increase* the energetic cost required to sustain basic physiological functions.

Living organisms avoid thermodynamic decay to grow and survive by consuming energy. The amount of energy expended relative to the minimal metabolic rate required to sustain life is defined as *metabolic efficiency*. Strong evolutionary pressures have optimized metabolic efficiency in organisms, thereby minimizing the amount of ATP required to sustain life [18]. One evolutionary strategy includes the choice of metabolic pathways to derive ATP (OxPhos vs glycolysis), which have different ATP yields and metabolic costs [19]. Within cells, metabolic costs arise mainly from transcription/translation processes (~60% of total energy demands), the maintenance of ionic balance, as well as organelle biogenesis and degradation [20,21], which includes mitochondrial turnover. Mitochondrial biogenesis comes at a substantial cost because of their extensive proteome [19]. In mitochondrial diseases, the intracellular heterogeneous mixture of mitochondria with mutant and wild-type mtDNA (i.e., heteroplasmy) triggers exaggerated biogenesis [22], a phenomenon predicted to increase the basal

metabolic cost of organelle maintenance and total energy expenditure [23]. Accordingly, resting energy expenditure (REE) in animal models of mitochondrial OxPhos dysfunction is elevated by 15-85%, including in Crif1$^{-/-}$ mice with impaired mitochondrial translation [10], Clpp$^{-/-}$ mice with deficient proteostasis [24], Polg mutator mice [10], ANT1$^{-/-}$ mice with impaired ATP/ADP exchange [25], and *ATP6*-mutant flies [26]. Therefore, we reasoned that similarly, patients with OxPhos defects would exhibit impaired metabolic efficiency and increased REE – a state known as *hypermetabolism*. Other causes of partial OxPhos dysfunction including mutations in nuclear genes encoding respiratory chain assembly factors like *SURF1* [27], which cause disease and decrease lifespan in humans [28], could also trigger hypermetabolism.

Shortened lifespan is a ubiquitous feature of mitochondrial diseases [29-31] and most animal models with OxPhos dysfunction die prematurely [32-35]. But is there a causal link between hypermetabolism and lifespan in humans? Among healthy individuals, elevated REE or hypermetabolism measured by indirect calorimetry (oxygen consumption, VO_2) predicts more rapid age-related physiological decline [36] and independently predicts 25-53% higher mortality over the following 20-40 years [37,38] – an effect double than that incurred by smoking cigarettes [38]. In human stem cells, hypermetabolism was also correlated with senescence and other aging phenotypes [39]. Mechanistically, multiple processes compete for limited energetic resources within cells [40,41], particularly under energy-restricted conditions. Because some cellular operations are prioritized over others [20], the energetic cost of stress responses and their associated increase in transcription/translation can inhibit growth and cell division, even triggering premature senescence [42,43]. Recently, it was reported that excessive activation of the ISR itself inhibits cell population growth [8]. Thus, OxPhos-induced ISR activation and the resulting hypermetabolism could curtail growth and/or cause premature death by forcing an energetic tradeoff between stress-related cellular recalibrations in competition with growth.

Taken together, the observations that: i) genetic mitochondrial OxPhos defects trigger integrated stress responses, ii) cells operate under energetic constraints where the prioritization of stress responses and transcription/translation costs can precipitate senescence, and iii) decreased metabolic efficiency predicts shorter lifespan in humans and other animals, lead to the following hypothesis for mitochondrial disease: genetic defects causing OxPhos dysfunction trigger hypermetabolism both physiologically and cell-autonomously, a phenotype associated with premature mortality.

Here we test this hypothesis by re-analyzing data from multiple clinical cohorts of primary mitochondrial diseases with direct and indirect assessments of energy expenditure and lifespan, and via longitudinal *in vitro* studies in patient-derived human fibroblasts. This cellular system provides high temporal resolution, repeated-measures of bioenergetic and multi-omic molecular recalibrations across the cellular lifespan. Using this model, we show that both genetic and pharmacological mitochondrial OxPhos defects trigger marked hypermetabolism in a cell-autonomous manner. We identify mtDNA

instability, activation of the ISR, increased secretory activity, and transcriptional upregulation of transcriptional/translational stress pathways as potential contributors to hypermetabolism. Finally, we report that OxPhos defects and hypermetabolism are linked to accelerated telomere shortening and epigenetic aging in fibroblasts, and provide a publicly available longitudinal dataset to query epigenetic and transcriptional signatures conserved across both cellular models. Together, these translational data implicate hypermetabolism as a pathophysiological feature of mitochondrial diseases.

Results

Meta-analysis of metabolic rate and physiology in primary mitochondrial disease

To test the hypothesis that mitochondrial OxPhos defects are associated with increased energy expenditure and shortened lifespan (**Figure 1A**), we integrated and re-analyzed data from a total of 17 cohorts representing a total of 690 subjects with mitochondrial diseases and 225 healthy controls (provided by the authors or directly from publications) (**Table 1**). The heterogenous mixture of functional and dysfunctional mitochondria within single cells is well known to cause mitochondrial hyperproliferation and increase mtDNA copy number [44-47], as illustrated within a single patient skeletal muscle cell in **Figure 1B**. Increased biogenesis must naturally incur increased energy expenditure at the cellular level [23], which we reasoned may translate to elevated whole-body REE.

In subjects with mitochondrial diseases, resting heart rate, which correlates with whole-body REE [48], was on average 10.7% higher than healthy controls ($p<0.01$, **Figure 1C**). This tachycardia reached up to +46% when patients and controls performed mild exercise at the same absolute workload (data not shown). Both at rest and during mild physical activity, as initially reported in a small study [49], patients had on average 244% higher blood or urine catecholamine levels ($p<0.05$, **Figure 1D**), particularly norepinephrine (NE), a neurohormone sufficient to elevate REE when administered systemically to healthy individuals [50]. To quantify REE in mitochondrial disease patients, resting whole body VO_2 expressed relative to body weight was used as it is the most direct available measure of mass-specific energy expenditure. Strikingly, VO_2 measured by indirect calorimetry across 6 cohorts of patients with mtDNA defects was on average 30% higher at rest ($p<0.0001$), a difference characterized by a very large effect size (Hedge's $g=2.4$, **Figure 1E**). Notably, elevated VO_2 was exaggerated by more than half (+51%) during mild physical activity in mitochondrial diseases (see Figure 1E). These substantially higher REE values reveal increased energy consumption (i.e., lower metabolic efficiency) in mitochondrial disease, at rest and particularly during mild physical challenges.



Figure 1. Meta-analysis of human studies reveals increased energy expenditure and shortened lifespan in primary mitochondrial diseases. (**A**) Overall conceptual model linking mtDNA- and nDNA-related OxPhos defects to impaired metabolic efficiency at the cellular level, impacting whole-body resting energy expenditure and clinical outcomes. (**B**) Skeletal muscle biopsy with individual muscle fibers stained with cytochrome c oxidase/succinate dehydrogenase (COX/SDH) histochemistry to reveal functional (brown) and respiratory chain deficient (blue) mitochondria. In the affected cell (middle), three sub-regions showing low, intermediate, and high mtDNA mutation load were captured by laser capture microdissection and subjected to quantitative PCR analysis as in (Picard et al. 2012). Subcellular regions with high mtDNA mutation load show elevated mtDNA density, which is predicted to increase the energetic cost due to maintenance and turnover processes. *WT*, wild type. (**C**) Meta-analysis of human mitochondrial disease cohorts showing elevated resting heart rate (n=104 controls, 111 patients), (**D**) catecholamines (urinary-Cohort 3 and blood-Cohort 6) at rest or during fixed-intensity exercise (n=38 controls, 19 patients), (**E**) whole-body oxygen consumption measured by indirect calorimetry at rest or during response to mild exercise challenge; [1] before training, [2] after training. *Slope* refers to the rate of increase in VO_2 relative to work rate, where a higher slope indicates increased energetic cost for a given work rate (n=56 controls, 78 patients). (**F**) Body mass index (BMI) across mitochondrial disease cohorts and compared to national averages (USA, UK, Italy) (n=285 controls, 174 patients). (**G**) Average life expectancy in individuals with mitochondrial diseases relative to national averages (n=301 patients). Data are means ± SEM, with % difference between mitochondrial disease and control group where available. (**H**) Mortality (age of death) over 10 years (2010-2020) in Cohort 17 compared to national averages for women and men (n=109 patients). See *Table 1* for cohort details. Total n=225 healthy controls, 690 patients. Groups compared by paired t tests (C and F) or one-sample t tests (D and E), * $p<0.05$, ** $p<0.01$, **** $p<0.0001$.

The increase in REE is particularly striking given that patients with mitochondrial diseases on average have lower muscle mass [17], which is the major site of activity-dependent energy consumption. Therefore, the lower muscle mass in patients would be expected to reduce energy expenditure, unless the tissues intrinsically exhibited impaired metabolic efficiency, and thus consumed more energy per unit time just to sustain homeostasis. Therefore, the meta-analysis of these clinical data from multiple cohorts combining hundreds of patients reveals an increased energetic cost of living per unit of body mass – or *hypermetabolism* – in mitochondrial diseases.

Physiologically, hypermetabolism is expected to produce a negative energy balance, expending more energy substrates than are ingested, generally preventing the accumulation of body fat. Accordingly, body mass index (BMI), a gross estimate of adiposity, was on average 9.8% lower ($p<0.05$) patients with mitochondrial diseases compared to controls (23% lower than national averages across 3 countries) (**Figure 1F**). In one study, fat mass index, a more precise indicator of body fat, was 21.9% lower in mitochondrial disease patients [17]. Moreover, although not all patients are thin, patients with more severe disease manifestations tended to have lower BMI ($r=-0.25$, $p=0.018$) [17], suggesting that more severe mitochondrial OxPhos dysfunction in humans contribute to override the propensity to obesity. Again, this result is in line with those in animal models of OxPhos defects, which similarly show hypermetabolism and reduced adiposity [10,24-26].

This clinical picture of mitochondrial diseases marked by increased REE and reduced body fat was associated with a 3-4-decade reduction in lifespan among adults (**Figure 1G**) [31]. In a 10-year longitudinal observational study from the UK, peak mortality in mixed genetic diagnoses of mitochondrial diseases occurs up to 3 decades earlier than the national reference (**Figure 1H**). In children with severe pediatric forms of mitochondrial diseases, including diseases caused by autosomal recessive respiratory chain defects (e.g., *SURF1* mutations: median lifespan 5.4 years [28]), lifespan can be reduced by >90%. Heterogeneity between genetic diagnoses also highlights possible mutation-specific effects on hypermetabolism (**Extended Data Figure 1**). Together, these multimodal physiological data establish hypermetabolism as a clinical feature of mitochondrial diseases, which could account for the rarity of obesity and also contribute to shortened lifespan in this population.

Longitudinal analysis of primary human fibroblasts with SURF1 mutations

To examine if mitochondrial OxPhos dysfunction alters the REE and lifespan in a cell-autonomous manner independent of clinical, medical, and socio-behavioral confounds, we next performed a longitudinal study of primary human fibroblasts with genetically-defined or pharmacologically-induced OxPhos dysfunction. We used cells with a stable nuclear mutation in *SURF1* (Surfeit Locus Protein 1), which causes partial mis-assembly and dysfunction of respiratory chain complex IV (cytochrome *c* oxidase, COX) [51] , leading to Leigh syndrome and death in early childhood

(see Figure 1G). Primary dermal fibroblasts were obtained from 3 patients with *SURF1* mutations presenting with Leigh syndrome, and from 3 healthy donors with no known mitochondrial dysfunction (*Control*) (**Extended Data Table 1-2**). Each group included one female and two male donors. To capture both baseline as well as trajectories of metabolic parameters across the entire lifespan, we passaged each fibroblast line over multiple cellular generations until growth arrest, a model that recapitulates *in vivo* molecular features of human aging, including canonical age-related changes in telomere length [52] and DNA methylation [53]. By sampling cells across the lifespan, longitudinal profiles of multiple cellular, bioenergetic, transcriptomic, epigenomic, and secreted molecular features can be modeled for each donor (**Figure 2A**). Although healthy cells survive for up to 250 days, here we limit our analyses to the maximal lifespan of *SURF1*-mutant cells, ~150 days.

Beyond allowing longitudinal assessments of molecular and bioenergetic parameters as cells transition from early-, mid-, and late-life, one major advantage of time-resolved trajectories with repeated-measures is that this approach de-emphasizes potential bias of any single time-point and provides more accurate estimates of stable cellular phenotypes for each donor and treatment condition. The use of primary human cells obtained from multiple donors, compared to the same experiment repeated in immortalized cell line(s), also provides a more robust test of generalizability of the data. Throughout the text, we report standardized measures of effect sizes (Hedge's g) where g>0.2 is considered a small, g>0.5 a medium, and g>0.8 represents a large effect size, which are considerably more informative to compare small groups (3 donors per group) [54].

SURF1 mutations cause hypermetabolism

We first examined the effect of *SURF1* mutations using extracellular flux analysis (Seahorse XF^{e}96) of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) (**Figure 2B-C**). Using standard stoichiometric ratios for oxygen consumed, protons pumped, and linked ATP synthesis under standard conditions, OCR and ECAR can be transformed into interpretable ATP production rates using the methods described in [55]. When added together, OxPhos-derived ($J_{ATP\text{-}OxPhos}$) and Glycolysis-derived ATP flux ($J_{ATP\text{-}Glyc}$) reflect the total energetic demand ($J_{ATP\text{-}Total}$) of each cell population (**Extended Data Figure 2A**)**.** This approach is the cellular equivalent to REE measurements through indirect calorimetry in humans (Figure 1E) and mice [10,24,25].

Trajectories of $J_{ATP\text{-}OxPhos}$ and $J_{ATP\text{-}Glyc}$ across 150 days of lifespan are presented in **Figure 2D**. As expected from the SURF1 deficiency, *SURF1*-mutant cells (hereafter SURF1 cells) exhibited a 44% decreased $J_{ATP\text{-}OxPhos}$, but a 3-4-fold increased $J_{ATP\text{-}Glyc}$. Both parameters remained relatively stable across the lifespan (although a potential oscillatory behavior cannot be ruled out). Computing total energy expenditure showed that total ATP demand per unit of time was strikingly 91% higher in SURF1 cells relative to control cells ($J_{ATP\text{-}Total}$, $p<0.001$, $g=2.4$) (**Figure 2E**). These data demonstrate a robust

SURF1-induced hypermetabolic state similar, albeit of greater magnitude, to that observed in patients with mitochondrial diseases.



Figure 2. SURF1 defects decrease metabolic efficiency and cause hypermetabolism without affecting coupling efficiency. (**A**) Schematic of the study design with primary human fibroblasts, coupled with repeated, longitudinal measures of cellular, bioenergetic, and molecular profiling across the lifespan. 3 Control and 3 SURF1 donors were used for all experiments. (**B**) Example oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) obtained from Seahorse measurements of Control and SURF1 cells. (**C**) Comparison of average OCR and ECAR values across the cellular lifespan. (**D**) Lifespan trajectories of ATP production rates (J_{ATP}) derived from glycolysis ($J_{ATP\text{-}Glyc}$), oxidative phosphorylation ($J_{ATP\text{-}OxPhos}$), and total ATP ($J_{ATP\text{-}Total}$: Glycolytic- + OxPhos-derived rates) over up to 150 days. Percentages show the average difference between SURF1 and Control across the lifespan. (**E**) Lifespan average energy expenditure (EE) by cell line, and (**F**) corrected for cell volume. (**G**) Balance of J_{ATP} derived from OxPhos and glycolysis and (**H**) quantified SURF1-induced metabolic shift. Dotted lines in (H) denote the range in control cells. (**I**) Lifespan trajectory of mtDNAcn and average mtDNAcn at the first 3 time points (early life, days 5-40) and peak value across the lifespan. (**J**) Lifespan trajectories and averages of proton leak and (**K**) coupling efficiency estimated from Seahorse measurements. n = 3 individuals per group, 7-9 timepoints per individual. Data are means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, mixed effects model (fixed effect of control/SURF1 group and days grown, random effects of donor or cell line).

To confirm this finding, potential confounds had to be ruled out. Non-glycolytic extracellular acidification rate (ECAR) could inflate estimates of $J_{ATP\text{-Glyc}}$[56]. However, measured resting non-glycolytic ECAR (in the absence of glucose or in the presence of the glycolysis inhibitor 2-deoxyglucose) was not elevated in SURF1 cells (it was in fact 31% lower), confirming the specificity of the ECAR signal in SURF1 cells to glycolysis (**Extended Data Figure 3D**). We also confirmed that non-OxPhos-related oxygen consumption by cytoplasmic and other oxidases did not differ between experimental groups (**Extended Data Figure 2D**). This parameter is not included in computing $J_{ATP\text{-OxPhos}}$, which formally excludes non-mitochondrial respiration as a potential contributor to the hypermetabolism measured in SURF1 cells.

Primary fibroblasts are continually dividing and a portion of total energy budget is expected to support cell division-related processes including DNA replication, transcription/translation, and other intracellular processes [20]. Early in life (20-50 days), when division rates were mostly constant, SURF1 fibroblasts compared to control cells divided on average 31.8% *slower* (P<0.0001, g=-1.53 and 48.4% slower when quantified across 150 days). Therefore, hypermetabolism in SURF1 cells cannot be accounted for by an accelerated division rate. In fact, normalizing $J_{\text{ATP-Total}}$ per rate of division further exaggerates apparent hypermetabolism, where SURF1 cells expend more than double the amount of energy than control to complete each cell cycle. Moreover, optically monitoring cell size at each passage showed that the SURF1 cell volume were moderately larger in early life and became smaller with increasing age, reaching similar volume as control cells by 150 days (**Extended Data Figure 4A**). Cell death was not significantly elevated (p=0.69, g=0.15, **Extended Data Figure 4D-E**). After accounting for cell volume, energy expenditure remained significantly elevated in SURF1 fibroblasts (p<0.0001, g=1.2, **Figure 2F**), demonstrating an increase in mass-specific REE. This increase is consistent in magnitude with that observed in humans (Figure 1) and animals [10,24-26] with OxPhos defects.

In control cells, the balance of estimated ATP derived from OxPhos and glycolysis was 64:36%, such that under our specific tissue culture conditions (5mM glucose, with glutamine, pyruvate and fatty acids), healthy fibroblasts derived the majority of ATP from OxPhos. In contrast, *SURF1* deficiency robustly shifted the relative OxPhos:Glycolysis contribution to 23:77% (p=4.1e-6, g=-5.1), reflecting a significant shift in OxPhos-deficient cells towards an alternative, and less energy efficient, metabolic strategy (**Figure 2G-H**). As expected, removing glucose from the media did not substantially affect growth in control cells, but the absence of glucose was lethal to SURF1 cells within 5 days, confirming their dependency on glycolysis for survival (**Extended Data Figure 3**).

In response to this metabolic shift towards glycolysis, we expected SURF1 cells to naturally decrease maintenance-related energetic costs by decreasing mitochondrial mass and mtDNA copy number (mtDNAcn). However, in early life, SURF1 cells had the same mtDNAcn as control cells (5-40 days, p=0.99, g=0.04). And across the lifespan, SURF1 cells contained 32% more mtDNA copies, which

manifested as an earlier age-related rise in mtDNAcn that reached maximal levels on average 30% higher than control cells (p=0.52, g=1.9, **Figure 2I**). Thus, although total mitochondrial mass was not directly assessed, elevated mtDNAcn similar to that observed in patient tissues (see Figure 1B) could contribute to increased maintenance cost and overall hypermetabolism in OxPhos-deficient cells, as suggested by mathematical modeling studies [23].

One potential mechanism for the lowered metabolic efficiency is a decrease in OxPhos coupling (i.e., uncoupling) at the inner mitochondrial membrane. However, both estimated proton leak (**Figure 2J**) and coupling efficiency (**Figure 2K**) measured by the proportion of OxPhos-dependent respiration not linked to ATP synthesis, were not different between control and SURF1 groups, and showed no measurable drift across the lifespan, thus ruling out mitochondrial uncoupling as a mechanism for hypermetabolism.

Inhibition of the mitochondrial ATP synthase triggers hypermetabolism

Next, to test if hypermetabolism is a specific manifestation in SURF1 cells or a more general feature of mitochondrial OxPhos dysfunction, we took an orthogonal pharmacological approach to chronically perturb OxPhos, and repeated the lifespan assessments of energy metabolism. Starting at day 20, fibroblasts from the same three healthy donors as above were treated chronically with a sublethal concentration of the mitochondrial ATP synthesis inhibitor oligomycin (Oligo, 1nM), which induces the ISR [3,57] (**Figure 3A**). Oligo reduced cellular oxygen consumption rate by ~90% while largely maintaining viability, reflected in only a moderate elevation in cell death over time (2.7% in Oligo-treated cells vs 1.4% in control cells, 20-50 days, p=0.078, g=0.70) (**Extended Data Figure 4D, 5B**).

In relation to energy expenditure, Oligo doubled $J_{ATP\text{-}Total}$ across the lifespan for each of the three healthy donors (+108%, p=5.9e-9, g=2.2), recapitulating the hypermetabolic state observed in SURF1 cells (**Figure 3B**). This robust elevation in cellular energy expenditure was already evident by 5 days of treatment and remained relatively stable across the lifespan, indicating the rapidity and stability of this adaptive hypermetabolic state. As in SURF1 cells, the hypermetabolic state in Oligo-treated cells was attributable to a markedly increased $J_{ATP\text{-}Glyc}$ in excess of the decline in $J_{ATP\text{-}OxPhos}$, resulting in a shift outside of the optimal (i.e., normal) window of the OxPhos:Glycolysis ratio for these cells (**Figure 3C-D**).

Reductions in cell size and division rates are strategies to minimize energetic costs. Oligo caused a small but stable 4.8% decrease in cell size (p<0.001, g=-0.35), and decreased cell division rates by 39.1% (days 20-50, p=1.3e-5, g=-1.31; 49.6% slower across 150 days) (**Extended Data Figure 4**). Taking cell size into consideration showed that Oligo increased energy expenditure per unit of cell volume by 131% (p<0.001, g=0.97) (**Figure 3E-F**). Here also, hypermetabolism was not driven by significant increase in estimated proton leak (p=0.19, g=0.27) (**Figure 3G**) although we observed a

34.4% reduction in estimated coupling efficiency ($p<0.05$, g=-0.59) (**Figure 3H**), likely arising from the expected elevation in membrane potential from ATP synthase inhibition. Unlike *SURF1* mutations, Oligo decreased mtDNAcn by 39.0% early in life (20-50 days, p=3.1e-5, g=-2.42), which subsequently normalized; peak levels were similar to control levels (**Figure 3I-J**).



Figure 3. Pharmacological inhibition of mitochondrial ATP synthesis triggers hypermetabolism. (**A**) Schematic of the study design for fibroblast profiling across the lifespan from 3 Control donors treated with 1nM oligomycin. (**B**) Lifespan trajectories of J_{ATP} (Glycolytic + OxPhos) derived from oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) obtained from Seahorse measurements across the cells' lifespan (up to 150 days). Percentages show the total average difference between Oligo and Control. (**C**) Balance of J_{ATP} derived from OxPhos and glycolysis across the lifespan and (**D**) Oligo-induced metabolic shift. Dotted lines denote the range in control cells. (**E**) Relative average lifespan energy expenditure by cell line normalized to control, (**F**) corrected for cell volume. (**G**) Average of proton leak and (**H**) coupling efficiency measures on the Seahorse normalized to control. (**I**) Lifespan trajectories and (**J**) average mtDNA copy number at the first 3 time points (early life) and peak value across the lifespan. n = 3 individuals per group, 7-9 timepoints per individual. Data are means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, mixed effects model for Oligo vs control.

Monitoring weekly the influence of Oligo on cell morphology also revealed an unexpected morphological phenotype. Oligo-treated cells developed into a reticular network, which involved contraction of the cell body and extension of multiple cellular appendages reminiscent of neuronal dendrites (**Extended Data Figure 5**). This reversible phenotype exhibited regular oscillatory behavior (one-week normal morphology, one-week reticular formation). We note that oscillatory behaviors are naturally energy-dependent [58], and that such dramatic and repeated changes in cell morphology must necessarily involve the remodeling of cell membranes and cytoskeleton through energy-dependent motor and cytoskeletal components. This morphological phenotype unique to the Oligo treatment could contribute to the higher energy expenditure in Oligo-treated cells (+131% ATP consumption per unit of cell volume) vs SURF1 (+91%).

OxPhos defects trigger the ISR and mtDNA instability

To understand the specific organelle-wide mitochondrial recalibrations in hypermetabolic SURF1 and Oligo-treated cells, we performed bulk RNA sequencing across the lifespan in each donor cell line (total 60 time points, average of ~7 timepoints per cell line). We then systematically queried mitochondrial pathways from MitoCarta 3.0 [59], in addition to all mtDNA-encoded transcripts (37 genes), and core ISR-related genes (ATF4, ATF5, CHOP/DDIT3, GDF15). Both *SURF1* defects and Oligo treatment downregulated the majority of intrinsic mitochondrial pathways, including mtDNA stability and decay, which was downregulated in both SURF1 (-15%, p=1.7e-8, g=-1.65) and Oligo-treated cells (-19%, p<0.001, g=-0.57) relative to control (**Figure 4A**). Although SURF1 and Oligo-treated cells exhibited similar overall mitochondrial transcriptional changes, some pathways showed opposite responses (e.g., expression of mtDNA-encoded genes, Pathway 3 in Figure 4B), suggesting the existence of partially specific mitochondrial recalibrations among SURF1 and Oligo models. In hierarchical clustering analysis across all pathways, the ISR pathway diverged most strongly from other pathways, and was upregulated +110% in SURF1 (p=6.5e-7, g=1.76) and +217% in Oligo-treated cells (p=1.2e-8, g=0.99), reaching up to a 16-fold elevation relative to the average of the young healthy donor cells (**Figure 4B**). Thus, both models of OxPhos dysfunction and hypermetabolism were associated with upregulation of the ISR, and downregulation of most mitochondrial pathways, notably mtDNA maintenance, suggesting a potential effect on mtDNA stability.

To our knowledge, neither *SURF1* mutations nor Oligo treatment are established to cause mtDNA instability, but given the transcriptional changes described above and that heteroplasmy among mtDNA species is predicted to increase energetic maintenance costs [23], we directly examined mtDNA stability using two approaches. We first used long-range PCR at multiple time points across the lifespan of control, SURF1, and Oligo-treated cells, then validated the presence of mtDNA deletions across the lifespan by mtDNA sequencing, and quantified mtDNA deletion burden using eKLIPse [60] (**Figure 4C-D**). Circos plots in **Figure 4D** show the break points and heteroplasmy level for each mtDNA deletion, at early and late time points along the cellular lifespan. Circos plots for all timepoints investigated (4-14 timepoints per condition) are presented in **Extended Data Figure 6**.

Consistent with previous work, healthy fibroblasts do not accumulate appreciable heteroplasmy levels of mtDNA deletions in culture. However, SURF1 cells contained on average 17-fold more unique mtDNA deletions than control cells (p<0.01, g=1.38), reaching up to 126 unique deletions at a given time point (**Figure 4E-F**). The effect of Oligo treatment was more modest but reached levels 3-fold higher than untreated cells (p<0.01, g=0.79), and up to 20 unique deletions per time point. The majority of deletions eliminated segments of the minor arc and were on average 6.8-7.3kb in length; deletion size was similar among the three groups (**Extended Data Figure 7A-C)**. Point mutations were not significantly elevated in SURF1 and Oligo-treated cells, suggesting specificity of mtDNA instability to

deletions (**Extended Data Figure 7D**). Compared to controls where the maximal heteroplasmy levels was 0.13%, SURF1 and Oligo accumulated individual deletions reaching up to 0.40% and 0.19% heteroplasmy among the cell population **(Extended Data Figure 7E-F**), which remains low but similar to that observed with aging in human blood and brain tissues [61,62], and possibly noteworthy for replicating fibroblasts.



Figure 4. Longitudinal mtDNA deletion profiles in OxPhos deficient SURF1 and Oligo cells. (**A**) RNAseq gene expression results for all MitoCarta 3.0 pathways, plus all mtDNA genes, and the integrated stress response (ISR, average of ATF4, ATF5, CHOP, GDF15). Values for each pathway are computed from the average expression levels of all genes in each pathway, expressed as the median-centered value relative to the youngest control timepoints for each pathway (rows). Each column represents a single timepoints (n=3-8) along the lifespan of each donor or treatment condition (n=9). (**B**) Gene expression time course of selected mitochondrial pathways from E, expressed on a Log2 scale relative to the first control timepoint (baseline). (**C**) 10Kb long range PCR product resolved by agarose gel electrophoresis for a control fibroblasts cultured up to 166 days (P3 to 31), and

passage-matched SURF1 and Oligo-treated cells. (**D**) Results from mtDNA sequencing and Eklipse analysis. Each line in the circos plots depict a deletion burden in control (Donor2) and SURF1 (Patient2) and Oligo-treated (Donor2) cells from two (early and mid-lifespan) representative passages. (**E**) Timecourse of the number of unique mtDNA deletions in control, SURF1, and Oligo-treated cells. (**F**) Total deletion burden in cells across 150 days of lifespan. Data are mean ± SEM. ** P < 0.01, *** P < 0.001, mixed effects model (fixed effect of Control/SURF1/Oligo group and days grown, random effects of donor or cell line).

SURF1 mutations increases aging-related secretory activity

We next investigated outputs of the ISR, including the production of metabokines and cytokines. To broadly characterize changes in the cytokine stress response in patient-derived SURF1 cells across the lifespan, we designed a custom Luminex array targeting age-related proteins identified by plasma proteomics to be upregulated with human aging [63] (**Figure 5**). Compared to healthy donors, hypermetabolic SURF1 cells secreted higher levels of cytokines on a per-cell basis, including several pro-inflammatory cytokines, chemokines, and proteoglycans associated with the senescence-associated secretory phenotype (SASP) [64] (**Figure 5A**). Of the 27 cytokines detected in extracellular media, SURF1 cells achieved the highest cytokine concentration across the lifespan for 23 (85%) of the cytokines, reaching up to 10-fold higher concentration than control for one of the cytokines (insulin-like growth factor binding protein, IGFbp-rp1) (**Figure 5B**). Upregulated cytokines also included the canonical pro-inflammatory cytokines IL-6 and IL-8. The metabokine GDF15, which is elevated in both mitochondrial disease [65,66] and human aging [63,67], and which also appears sufficient to trigger hypermetabolism in mice [10], was also upregulated by 110% in SURF1 vs control cells (20-80 days, p=0.035, g=1.0, **Figure 5C**).

We attempted to validate IL-6 and GDF15 levels in both SURF1 and Oligo-treated cells by ELISAs. The ELISAs confirmed that IL-6 increased exponentially in aging fibroblasts, displaying altered onset and trajectories in both SURF1 (upregulated) and Oligo-treated cells (downregulated) (**Figure 5D**). Compared to control fibroblasts where GDF15 was undetectable in early passages, SURF1 mutant fibroblasts began to secrete GDF15 prematurely, and Oligo treatment acutely induced robust GDF15 secretion by 1-2 orders of magnitude over the first few weeks (**Figure 5E)**, consistent with the rapid induction of the ISR particularly in Oligo-treated cells (see Figure 4B).

As cell-free mitochondrial DNA (cf-mtDNA) is associated with human aging [68] and was recently found to be elevated in the plasma of patients with mtDNA mutations/deletions [69], we quantified cf-mtDNA in the media along the lifespan. Both mtDNA and nDNA were detectable at appreciable levels (**Extended Data Figure 8A-B**). Compared to media of control cells, cf-mtDNA levels were 73% higher in SURF1 (g=0.5) and 100% higher (g=0.3) in the media of Oligo-treated cells (**Figure 5F**), although these differences did not reach statistical significance due to the high temporal variation of this phenotype. Parallel measurements of cell-free nuclear DNA (cf-nDNA) showed that the released mitochondrial-to-nuclear genome ratio was on average 117% higher in SURF1 than control cells

(p<0.01, g=0.85, **Extended Data Figure 8C-D**), indicative of selective mtDNA release. Given the energetic cost associated with protein secretion [21,70], we suggest that the cytokine/metabokine and mtDNA hypersecretory phenotype in SURF1 and Oligo cells must contribute to hypermetabolism along with other cellular processes.



Figure 5. OxPhos defects trigger hypersecretion of metabokines and age-related cytokines. (**A**) Cytokine dynamics across the lifespan measured on two multiplex (Luminex) arrays. Cytokine levels are normalized to the number of cells at the time of sampling, shown as Log_2 median-centered for each cytokine; samples with undetectable values are shown as grey cells. Columns represent repeated-measures (n=6-8) along the lifespan of each controls and SURF1 donor (n=3 per group). (**B**) Comparison of maximum cytokine concentration reached in each of the SURF1 and healthy control donors, showing general upregulation of most metabokines and cytokines. The value for TGF-α is heavily influenced by a single very high value in Donor 3. (**C**) Cell-free GDF15 time course as measured on the Cytokine array. Inset compares early release between 20-80 days. (**D**) Media GDF15 levels across the cellular lifespan measured by enzyme-linked immunosorbent assay (ELISA), normalized to the number of cells at time of sampling. Samples with non-detectable values (N.D.) are shown as zero values. (**E**) Media IL-6 levels across the cellular lifespan by ELISA, normalized to the number of cells at time of sampling. (**F**) Cell-free mitochondrial DNA dynamics across the cellular lifespan using qPCR, normalized to the number of cells at time of sampling. n = 3 per group, 6-13 timepoints per condition. Data are means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, mixed effects model (fixed effect of Control/SURF1/Oligo group and days grown, random effects of donor or cell line).

Abbreviations: *CCL7*, C-C motif chemokine ligand 7; *IL-8*, interleukin 8; *CHI3L1*, Chitinase-3-like protein 1; *MMP7*, Matrix metallopeptidase 7; *IL-6*, Interleukin 6; *IGFBP-rp1*, Insulin-like growth factor binding protein 7; *TNF-RII*, tumor necrosis factor receptor superfamily member 1B; *TGF*-α, Tumor growth factor alpha; *IFN-γ*, Interferon gamma; *TNFRSF9*, TNF receptor superfamily member 9; *GDF-15*, growth differentiation factor 15; *TNF-β*, Tumor necrosis factor beta; *Fas*, Fas cell surface death receptor; CCL3, C-C motif chemokine ligand 7; FSTL1, Follistatin

like 1; CCL23, C-C motif chemokine ligand 23; TIMP-1, Tissue inhibitor of metallopeptidase 1; *CD163*, CD163 antigen; *Lumican*, keratan sulfate proteoglycan Lumican; *IL-18*, Interleukin-18; *CXCL16*, C-X-C motif chemokine ligand 16; *Fetuin A*, Alpha 2-HS glycoprotein; *ALCAM*, activated leukocyte cell adhesion molecule; *TNF-RI*, TNF Receptor Superfamily Member 1A; *PCSK9*, Proprotein convertase subtilisin/kexin type 9; *TFPI*, Tissue factor pathway inhibitor.

OxPhos defects upregulate energy-demanding cellular programs

From our longitudinal RNAseq dataset, we noted changes in the totality of genes related to the ribosomal machinery, which is produced in proportion with cellular biosynthetic demands (**Extended Data Figure 9A**). Despite their significantly reduced growth rate, both SURF1 (+19%, p=2.4e-10, g=2.59) and Oligo-treated cells (+50%, p<0.01, g=0.86) showed a marked time-dependent upregulation in the ribosomal machinery, consistent with the hypersecretory phenotype (secreted proteins must be transcribed and translated) and the elevated metabolic demands of translation that is in competition with cell growth [42,70] (**Extended Data Figure 9B**). To characterize the genome-wide gene regulatory changes associated with these cellular phenotypes, and to gain insights into the potential cause(s) of hypermetabolism in response to OxPhos dysfunction, we next deployed time-sensitive models of gene regulation and DNA methylation.

We first visualized the transcriptomic profiles of SURF1 and Oligo-treated cells using t-distributed stochastic neighbor embedding (t-SNE). Spatial embedding along the two major tSNE components captured three main features of the transcriptome: i) substantial interindividual differences separating each donor/cell line, ii) age-dependent shifts in transcriptional profiles, iii) clustering among both SURF1 and Oligo cells (**Figure 6A**). To harness the longitudinal nature of these data, we used a linear mixed effects model (LMER) to identify time-dependent differentially expressed genes (DEGs, FDR<0.05 threshold) between SURF1 and Oligo relative to control, across the cellular lifespan (**Supplemental Files 1-2**). Consistent with the similar degree of hypermetabolism and metabolic shift of both cellular models (see Figures 2D-F and 3B-F), there was a relatively high degree of overlap in DEGs between SURF1 and Oligo-treated cells (**Supplemental Files 3-4**). Genes with the largest effect sizes conserved across SURF1 and Oligo showed up to 2-4-fold upregulation (39%, n=1,503) or downregulation (35%, n=1,344) (**Figure 6B-C**). Differences were larger and more stable between SURF1 and control, compared to more progressive effects following the beginning of the Oligo treatment (**Extended Data Figure 10**), consistent with the constitutive genetic deficiency in SURF1 cells compared to the novel insult with Oligo treatment. The effects of OxPhos dysfunction on the expression of the 37 mtDNA genes across the cellular lifespan are shown in **Extended Data Figure 11**.

To gain insight into the molecular underpinnings of hypermetabolism, we analyzed gene expression changes using iPAGE, an information-theoretic computational framework that enables the systematic discovery of perturbed cellular pathways from gene expression data [71]. Both SURF1 and Oligo-treated cells displayed a significant perturbation of transcription and translation processes (**Figure**

6D). Upregulated genes were enriched for pathways related to Golgi vesicle transport, fibroblast growth factor (FGF) binding, VEGF receptor signaling pathway, and the unfolded protein response, a signature consistent with increased secretion and inter-cellular signaling activity. Downregulated genes were over-represented for processes relating to cell division, consistent with the slower division rates (i.e., quiescence or senescence) of SURF1 and Oligo-treated cells.



Figure 6. Mitochondrial defects trigger conserved transcriptional remodeling. (**A**) t-distributed stochastic neighbor embedding (t-SNE) of RNAseq data from control, SURF1, and Oligo-treated human fibroblasts across the lifespan. (**B**) Overlap of significantly upregulated (red) or downregulated (blue) genes in SURF1 and Oligo groups relative to control (linear mixed effects model, FDR-corrected p value < 0.05). Note, outer group counts include shared counts in overlapping ring. Gray indicates diverging direction of regulation between SURF1 and Oligo DEGs. (**C**) Expression levels of the top 100 differentially-expressed genes in SURF1 (<75 days grown) and Oligo-treated cells (days 35 to 110). (**D**) iPAGE analysis of RNAseq data showing the top 40 enriched gene ontology pathways in top overlapping up- and down-regulated genes, conserved across both SURF1 and Oligo groups relative to control. Note, -log(p value) > 8 are mapped as dark orange. (**E**) Gene expression timecourses of select genes related to the ISR, senescence, nucleotide metabolism, and telomere maintenance. Log2 expression values (TPM) are normalized to the median of controls youngest timepoints. n = 3 donors per group, 3-8 timepoints per donor.

Lifespan gene expression trajectories in this dataset showed some noteworthy features of OxPhos dysfunction and hypermetabolism at the single-gene level: i) ISR-related genes are robustly upregulated in a time-dependent manner by up to ~16-fold for the transcription factor CHOP (DDIT3), and ~60-fold for its downstream target GDF15; ii) the age-related upregulation of senescence-related

genes (e.g., p21/CDKN1A) occurs prematurely in hypermetabolic SURF1 and Oligo cells; iii) key nucleotide metabolism enzymes such as thymidine kinase 1 (TK1) are robustly downregulated in SURF1 cells, possibly contributing to mtDNA instability [72]; and iv) telomere and longevity-related genes such as the metabolic sensor SIRT1 and the telomere protection complex component CTC1 are upregulated 2-4-fold (**Figure 6E**). These broad changes in gene expression, largely consistent with previous *in vitro* work [3,73], prompted us to examine another major layer of gene regulation, DNA methylation.

DNA methylation recalibrations in OxPhos-induced hypermetabolism

To examine nuclear DNA methylation (DNAm) and create a resource dataset with broad utility, we measured DNA methylation levels at 865,817 CpG sites (Illumina EPIC array) in Control, SURF1, and Oligo-treated cells at multiple time points across their cellular lifespan (n=66). We then leveraged these high dimensional data by building mixed-effects models that consider the underlying data structure (donors, longitudinal observations) to identify robust conserved DNA methylation changes associated with OxPhos dysfunction and hypermetabolism. Visualizing the general data structure using t-SNE showed, that: i) the methylome signature of each donor was relatively distinct; ii) DNAm exhibited consistent age-related shifts, iii) SURF1 cells clustered separately from control, while iv) Oligo cells caused a modest time-dependent shift away from their respective controls (**Figure 7A**). These data therefore add to previous evidence in HEK293 cells[74] and mice[75], providing a robust platform for discovering conserved nuclear DNAm effects of hypermetabolism-causing OxPhos defects in primary human cells.

At the single CpG level, we asked which differentially methylated positions (DMPs) were stably and consistently either hypo- or hypermethylated in both SURF1 or Oligo-treated cells relative to control. Because transcriptionally relevant DNAm changes may operate across multiple CpGs, we complemented this approach by systematically examining differentially methylated regions (DMRs), which include multiple nearby CpGs exhibiting similar hypo- or hypermethylated changes in our statistical model [76] (see *Methods* for details). **Figure 7B** shows the overlap in significant DMPs and DMRs (threshold FDR<0.05). Of the overlapping DMPs between SURF1 and Oligo, 14.8% were hypermethylated, and 45.9% were hypomethylated. Global hypomethylation is a feature of human aging and replicative senescence [53]. For DMRs, the corresponding proportions were 11.1% and 46.6%, showing high agreement in the methylome recalibrations between DMPs and DMRs approaches. A notable number of significant and highly differentially methylated changes in either SURF1 or Oligo-treated cells were specific to each condition (**Supplemental Files 5-10**), but here we focus exclusively on the changes conserved across two independent models, which therefore have the highest probability of being specifically caused by OxPhos dysfunction and related to hypermetabolism (**Figure 7C-D**).



Figure 7. Mitochondrial defects trigger conserved epigenetic remodeling. (**A**) t-distributed stochastic neighbor embedding (t-SNE) of methylome from control, SURF1-disease (<75 days grown), and oligomycin (35to110 days grown) treated fibroblasts across replicative lifespan**.** (**B**) Venn diagrams for differentially methylated CpGs (DMPs, left panel) and differentially methylated regions (DMRs, right-panel) generated from mixed effects modeling. Note, outer group counts include shared counts in overlapping ring. (**C**) Heatmap of top 100 DMPs in SURF1-disease and Oligomycin-treated. DMPs ordered by mean methylation difference between groups. (**D**) Timecourse of top 3 hyper- and hypo-DMPs for SURF1 disease and oligomycin. (**E**) Gene regional map of top hyper- and hypo-DMRs for SURF1-disease and Oligomycin-treated fibroblasts. 5'->3' direction. (**F**) Heatmap of top 20 enriched gene ontology pathways in top 1000 hyper- and hypo-DMPs & DMRs overlapping between SURF1 and Oligomycin. Note, -log(Pvalues) > 10 are mapped as dark orange. n = 3 donors per group, 5-11 timepoints per donor/treatment.

The most robust changes in DNA methylation were targeted at CpG islands near or on gene bodies. Relative to control cells, as in the RNAseq results, the effect sizes were larger for SURF1 compared to Oligo, which induced directionally consistent but smaller effect size changes than *SURF1* defects (**Figure 7E**). A stringent analysis of the most differentially methylated genes (based on both DMSs and DMRs) showed strong enrichment for processes involving: i) development and morphogenesis, ii) regulation of cell-cell signaling and organismal communication, iii) neural development, and iv) cell adhesion (**Figure 7F**). As highlighted above, increased regulation of signaling and communication, along with development and morphogenesis, must entail energetically dependent processes. These data, supported by the activation of corresponding downstream transcriptional programs (Figure 6) and the observed hypersecretory phenotype in OxPhos-deficient cells (Figure 5),

document genome-wide epigenomic recalibrations consistent *not* with energy conservation, but with increased total energy expenditure.

RC dysfunction accelerates telomere shortening and decreases lifespan

Finally, given the deleterious effect of hypermetabolism-causing OxPhos defects on lifespan in patients with mitochondrial diseases and in animal models, these genome-wide data prompted us to examine how hypermetabolism relates to genomic markers of cellular aging and senescence. The complete population doubling curves of each donor (**Figure 8A**) provided initial evidence that cellular lifespan was reduced in SURF1 and Oligo-treated cells. The Hayflick limit (i.e., total number of cell divisions [52]) was on average 53% lower in SURF1 cells (p=0.072, g=2.0), and Oligo decreased the Hayflick limit by 40% (p<0.066 g=2.0) relative to the untreated cells of the same donor (**Figure 8A-B**). Interestingly, the magnitude of these effects (40-53%) on total population doubling loosely corresponds to the 3-4-decade loss in human lifespan documented among adults with mitochondrial diseases (see Figure 1G-H), which would represent 38-50% for an average 80-year life expectancy.



Figure 8. Mitochondrial OxPhos defects decrease lifespan and accelerate telomere shortening. (**A**) Growth curves of control, SURF1, and Oligo-treated cells. Population doublings were determined from both live and dead cell cells at each passage. (**B**) Hayflick limit defined as the total number of population doublings achieved before division rate <0.01 divisions/day for at least two passages. (**C**) Telomere length (**C**) per population doubling, (**D**) rate of telomere attrition per division, and (**E**) terminal telomere length. (**F**) Rate of epigenetic aging for control, SURF1, and oligo-treated cells, calculated from the linear rate between days 25-75 (3-4 timepoints/cell line). (**G**) Average rate of epigenetic aging across all PC-based clocks. Each datapoint represents a different clock. (**F-G**) Significance values were calculated using a multiple comparison two-way anova. n=3 donors per group, 5-15 timepoints per condition for telomere length. In D, data are the slope estimate for the linear regressions in C. Data are means ± SEM. * P < 0.05, ** P < 0.01.

To directly measure the pace of biological aging in response to OxPhos defects, we performed repeated-measures of telomere length across the cellular lifespan, which allowed us to compute the average *rate* of telomere shortening per population doubling or cell division (**Figure 8C**). Consistent with observations of dramatically shortened telomeres in skeletal muscle of patients with mtDNA mutations [77] and recent work causally linking mitochondrial dysfunction to telomere dysfunction [78], both

SURF1 mutations and Oligo treatment strikingly increased the rate of telomere erosion per population doubling by 162% (SURF1: p=0.53, g=3.2) and 769% (Oligo: p=0.09, g=1.2) (**Figure 8D**). This means that for each cell division, OxPhos-deficient hypermetabolic fibroblasts lose 1.6-7.7 times more telomeric repeats than healthy fibroblasts. We note that these results rely on the estimated slope across the whole cellular lifespan (single value per donor, n=3 per group) so the p values are less meaningful than the effect sizes, which are large (>1). The terminal telomere length coinciding with growth arrest tended to be moderately higher in SURF1 and Oligo groups (**Figure 8E**). This could suggest that growth arrest is driven by factors other than absolute telomere length, such as the prioritization of transcription/translation over growth-related functions, sufficient to induce growth arrest and senescence in human fibroblasts [42,43].

Next, we leveraged our DNAm dataset to quantify biological age using validated multivariate algorithms or "clocks" (DNAmAge, or epigenetic clocks) trained, in human tissues, to predict chronological age and mortality [53,79]. Five different validated clocks that rely on different CpG sets and include a modification that improves their accuracy [80] were applied directly to our fibroblast time series DNAm data. These results showed that relative to the rate of epigenetic aging in control cells with normal OxPhos function, the rates of biological aging per population doubling were accelerated by an average of 131% in SURF1 cells (p<0.05, g=1.5), and to a lesser extent in Oligo-treated cells (+54%, p<0.05, g=0.6, **Figure 8F-G**), independently supporting the findings of accelerated telomere shortening. Trajectories and DNAm aging rates for each donor using all five epigenetic clocks, including those computed relative to "time in culture" rather than to population doublings, produced variable results and are presented in **Extended Data Figure 12**.

Together, the decreased Hayflick limit, the accelerated telomere attrition rate, and increased rate of epigenetic aging converge with the secretome analysis and senescence-related gene expression to link mitochondrial hypermetabolism-causing OxPhos dysfunction to reduced cellular lifespan.

Discussion

Integrating available clinical and animal data together with our longitudinal fibroblast studies has revealed hypermetabolism as a conserved feature of mitochondrial OxPhos dysfunction. A major advantage of our cellular system is that it isolates the stable influence of genetic and pharmacological OxPhos perturbations on energy expenditure, independent of other factors that may operate *in vivo*. Thus, these data establish that OxPhos dysfunction induces hypermetabolism in a cell-autonomous manner. Moreover, despite the diverging mode of action of SURF1 and Oligo models, as well as some divergent molecular features, both models converge on the same hypermetabolic phenotype, adding confidence around the generalizability of this phenomenon. Our data also rule out mitochondrial

uncoupling as a main driver of hypermetabolism in this system, and instead implicates the activation of energy-demanding gene regulatory programs, including but likely not limited to increased metabokine/cytokine secretion, that can compete with growth and longevity (**Figure 9**). Although phenomenological in nature, our cellular lifespan data provide several novel observations that agree with previous work [73], and that are relevant to understanding how primary mitochondrial OxPhos dysfunction triggers some of the physiological and phenotypic hallmarks of mitochondrial diseases.



Figure 9. Conceptual model including potential sources of hypermetabolism in cells and patients with mitochondrial diseases. OxPhos defects trigger mtDNA instability and cell-autonomous stress responses associated with the hypersecretory phenotype, recapitulating findings in plasma of patients with elevated metabokine and cell-free mitochondrial DNA (cf-mtDNA) levels. These responses are linked to the upregulation of multiple energy-dependent transcriptional programs, including the integrated stress response (ISR). We propose that these processes collectively increase energy consumption, leading to *hypermetabolism* in patient-derived fibroblasts, and physiological hypermetabolism in affected patients. In dividing human fibroblasts, hypermetabolism-causing OxPhos defects curtails lifespan and accelerate canonical cellular senescence and aging markers, namely telomere length and epigenetic aging.

First, we observed that the mitochondrial disease marker GDF15 was largely undetectable in the media of young, healthy fibroblasts, but increased progressively across the cellular lifespan. This finding recapitulates the age-related increase in GDF15 in humans [63,67], and adds to previous evidence of conserved age-related changes in DNA methylation in primary human fibroblasts cultured over several months [53]. Consistent with the higher GDF15 levels in primary OxPhos disorders in humans [66] and mice [10], extracellular GDF15 tended to be elevated in both models of OxPhos dysfunction. Likewise,

OxPhos dysfunction increased extracellular cf-mtDNA levels, in line with recent reports that cf-mtDNA is elevated in primary OxPhos disorders [69] and with aging in humans [68]. The link between OxPhos dysfunction and cf-mtDNA release requires further investigation.

Second, we observed that OxPhos dysfunction from *SURF1* mutations, and to a lesser extent Oligo treatment, both caused secondary mtDNA instability. mtDNA instability was associated with the variable accumulation of mtDNA deletions, but not point mutations, across the cellular lifespan. Our confidence in this result is reinforced by the longitudinal nature of the mtDNA sequencing data, from the same primary cell lines examined at multiple time points. Notably, the time course data also showed that cell populations can eliminate a large fraction of mtDNA deletions within 12-14 days (different mtDNA deletions appear at different passages). This is consistent with the fact that replicating fibroblasts eliminate some deleterious mtDNA deletions [81], and also that several *de novo* deletions removed the origin of replication of the light strand (O_L), thereby preventing their replication. Whether the clonal amplification of some mtDNA deletions in SURF1 fibroblasts occurs through population selection at the cellular level, or through intracellular quality control mechanisms, or a combination of both, remains to be determined.

Third, mitochondrial OxPhos dysfunction dramatically increased the telomere erosion rate per cell division, despite the adaptive transcriptional upregulation of telomere protection complex components. This finding agrees with a role of mtDNA on telomere maintenance in conplastic mice [82], with the life-shortening effect of pathogenic mtDNA variants [32] and OxPhos dysfunction in mice [34], and with the reduced lifespan in patients with mtDNA disease shown in Figure 1G-H. A study in skeletal muscle of children with high heteroplasmic mtDNA mutations also reported excessively short telomeres, similar in length to the telomeres of healthy 80 year old controls [77]. Because skeletal muscle is a post-mitotic tissue, this previous result also implies that OxPhos dysfunction could accelerate telomere attrition at a disproportionate rate, or perhaps independent from cell division, as suggested by the disconnect between the loss of telomeric repeats and genome replication/cell division observed in our hypermetabolic fibroblasts.

Why OxPhos-induced hypermetabolism is associated with both mtDNA instability and accelerated telomere erosion remains unclear. One potential principle at play may relate to the fact that DNA maintenance (mtDNA, and telomeres) relies on the accuracy of the molecular processes that ensure accurate mitochondrial and nuclear DNA replication. The energetic tradeoff between translation and growth [42] could explain why OxPhos-deficient cells, which expend a large fraction of their energy budget to upregulate transcription/translation and secretory, also grow more slowly. DNA replication is also constrained and sits at the bottom of a hierarchy of energy-consuming processes where vital processes, such as ionic balance and translation, are prioritized over division and DNA replication [20]. Furthermore, cells under stress experience an energetic tradeoff between the accuracy of molecular

operations and the speed of these processes, known as the energy-speed-accuracy tradeoff [83]. Although it is currently not possible to mechanistically test this point, we speculate that the diversion of energetic resources, as well as substrates including nucleotides [72], contributes to reduced DNA replication fidelity, which in turn could contribute to both mtDNA instability and telomere attrition.

Fourth, our longitudinal RNASeq and DNAm datasets revealed conserved recalibrations implicating developmental and translation-related pathways, as well as cell-cell communication, with OxPhos dysfunction and hypermetabolism. The identified pathways overlap with previously identified multi-omic overrepresentation analysis performed on iPSC-derived neurons from SURF1 patients [84]. In both this and our study, multi-omic analyses identified neural development, cell signaling, morphogenesis, cell cycle, and metabolism as the predominant processes altered in *SURF1*-related disease. The induction of these energetically-demanding pathways that constrain growth at the cellular and possibly at the organismal level [41], could help explain why a major feature of pediatric mitochondrial disorders (including our SURF1 donors) is developmental delay, and why short stature is common in adult patients [30]. In relation to cell-cell communication, we note that the biomarker picture of adult patients with mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is dominated by *elevated* (not reduced) signaling and metabolic markers in blood [66]. Thus, the organism under metabolic stress does not turn to an energy-saving *hypometabolic* state, but instead activates energivorous integrated stress responses that must divert and consume energetic resources, in a tradeoff with other processes such as growth and longevity pathways.

Finally, OxPhos dysfunction triggered a shift towards glycolytic ATP production. The glycolytic shift in fibroblasts is consistent with the physiological shift in substrate oxidation from lipids/amino acids to carbohydrates (whole body respiratory quotient) among patients [85] and mice [86] with OxPhos defects. The active shift towards glycolysis occurs even when OxPhos is *not* completely obliterated. For example, although basal respiration was markedly lower in SURF1 cells, the maximal FCCP-uncoupled respiration in SURF1 cells was relatively preserved (see Figure 2B & Extended Data Figure 2C). This cellular decision to route metabolic flux towards an energetically less efficient pathway (i.e., glycolysis) can be explained on the basis of energetic constraints and proteome efficiency, since the proteome cost of OxPhos is at least double that of glycolytic fermentation [19]. Thus, cells can “choose” to divert metabolic flux towards glycolysis even when OxPhos is at least partially functional, as in cancer, because of rising intracellular energetic constraints driven by hypermetabolism. We note again that hypermetabolism is apparent across multiple animal models of primary OxPhos dysfunction, manifesting as an elevated cost of living, even during rest and sleep in mice [10,24-26]. In particular, deep phenotyping of *Ant1*$^{-/-}$ mice across three studies [25,87,88] reveals a systemic physiological picture highly consistent with mitochondrial diseases, including excessive mitochondrial biogenesis, elevated circulating catecholamine levels, severe hypermetabolism (+82-85% REE), reduced adiposity, elevated

mtDNAcn and mtDNA instability, and decreased median lifespan. These *in vivo* data provide direct converging evidence, beyond the clinical data (Figure 1), that mitochondrial OxPhos dysfunction impairs whole-body energetic efficiency and cause physiological hypermetabolism.

Identifying hypermetabolism as a feature of mitochondrial disease has potential clinical utility as it provides a potential basis to explain some of the major symptoms in patients. *First*, fatigue and exercise intolerance are evolutionary conserved and subjective experiences that arise when the organism consumes more energy than it would under optimal conditions (e.g., subjective fatigue during the oxygen debt after strenuous exercise, or during an infection). Thus, symptoms of fatigue could be direct consequences of impaired metabolic efficiency and hypermetabolism. *Second*, as noted above, severely affected patients with mitochondrial disease are usually thin, which may be attributable to not only reduced energy intake or to intestinal malabsorption, but to chronic hypermetabolism, effectively burning excess ingested calories, preventing the accumulation of excess adiposity. *Third*, alcohol appears to be poorly tolerated and associated with symptom onset in some patients with mtDNA defects [89-91], but the basis for alcohol intolerance remains unknown. Alcohol itself causes hypermetabolism in healthy individuals – increasing whole-body REE by as much as 16%, and inhibiting lipid oxidation by 31-36% [92,93]. Alcohol may therefore aggravate pre-existing hypermetabolism, thus imposing further energetic constraints on vital cellular or physiological functions. Finally, chronic hypermetabolism could in part explain why infections can trigger symptoms exacerbations, representing the major cause of decompensation and death in this population [29]. The metabolic cost of immune activation to viral and bacterial infection is high, and cytokine production in human leukocytes is under mitochondrial regulation [94]. Thus, immunity must therefore compete with other host maintenance systems [95]. We speculate that in mitochondrial diseases, because the more limited energetic resources are consumed at a higher rate than normal due to hypermetabolism, patients may particularly lack the necessary energetic reserve required to sustain vital organs while mounting adequate immune responses.

Together, the meta-analysis of clinical data from 17 cohorts and two cellular models of OxPhos dysfunction identify hypermetabolism as a feature of mitochondrial disease. Our longitudinal patient-derived fibroblasts data further delineate some of the cellular and molecular features of OxPhos-induced hypermetabolism, including sustained induction of the ISR, genome instability, hypersecretion of cyto/metabokines, and genome-wide DNA methylation and transcriptional recalibrations that emphasize the upregulation of processes related to signaling and communication (see Figure 9). A resource webtool with all data from this study, including the RNAseq and DNAm data, is available and can be explored for genes or processes of interest (see *Data Availability Statement*). Although further work is needed, these descriptive translational data provide a basis to rationalize some unexplained clinical features of mitochondrial diseases, providing a foundation to design well-controlled studies to

understand to what extent hypermetabolism is a harbinger of morbidity and early mortality in patients with mitochondrial diseases.

Limitations. The major limitation of this work is the lack of mechanistic data about the origin of hypermetabolism, or about the relative contributions of specific signaling pathway(s) and cellular process(es) that drive elevated energy consumption in OxPhos deficient cells and humans. The extracellular flux analysis used to derive ATP consumption rates are also indirect [56], and metabolic tracing experiments are likely to yield useful information to better understand energy consumption and partitioning in hypermetabolic cells. Rather than pursuing a single potential mechanistic explanation for this phenomenon, motivated by the consistent evidence in clinical and animal studies, we attempted to deeply phenotype both cellular models of hypermetabolism and to produce an abnormally broad dataset (also an unusually long manuscript) covering key processes and pathways previously implicated in the pathogenesis of OxPhos defects. Deployed longitudinally across multiple donors, this publicly available dataset can now be used to rationally design testable hypotheses about the origin(s) and consequence(s) of hypermetabolism in OxPhos defects, to be tested in cellular and animal models, and eventually in humans. The small sample size and the *in vitro* nature of the cellular data can also be regarded as limitations of this work, potentially limiting generalizability. However, the stability of metabolic and molecular phenotypes in two distinct experimental models, across three unrelated donors (female and male) repeatedly monitored across the replicative lifespan – when cells undergo dynamic age-related changes – is a strong test of robustness for this finding. Finally, we note that the clinical phenotyping presented in Figure 1 is not exhaustive, focusing exclusively on clinical outcomes related to energy expenditure. Much work remains to fully define the clinical heterogeneity, as well as the neuroendocrine and metabolic manifestations of hypermetabolism. Therefore, our translational findings highlight more than ever the need for collaborative, multi-center partnerships that bridge the cellular, clinical, as well as the patient-reported aspects of mitochondrial diseases.

Methods

Human cohorts

Data were meta-analyzed from 17 mitochondrial disease cohorts listed in Table 1. Inclusion criteria included 1) cohorts with a genetic diagnosis for all participants and 2) including measures for at least one of the primary outcomes (resting heart rate, catecholamine levels, resting VO_2 or VO_2 relative to work rate, BMI, mortality). Eligible cohorts included participants from 5 countries including China, Denmark, England, Italy, and the USA. Studies were published between 2003 and 2019, covering a 16-year period. Each cohort with its sample size, female/male distribution, genetic diagnoses (nDNA vs mtDNA), and symptomatology is listed in Table 1, with additional information about data extraction provided here. Each cohort included their own control group, so group level averages (not patient-level data) were use to compute effect sizes as % difference between mitochondrial diseases and control, and standardized Hedges g for each outcome measure (e.g., resting heart rate, resting VO_2). Cohorts with available source data to calculate intragroup variance include error bars denoting standard error of the mean in Figure 1.

Cohort 1 [96] included data on resting HR and resting VO_2 in patients with mixed genetic defects. *Cohort 2* included four sub-studies: a) [97], b) [98], c) [99], and d) an unpublished cohort of patients with single large-scale mtDNA deletions with measures of resting HR, resting VO_2, and BMI. *Cohort 3* [100] included data on resting HR, resting urinary catecholamines, and BMI. *Cohort 4* [101] included data on resting HR and BMI. *Cohort 5* is an unpublished cohort (the Mitochondrial Stress, Brain Imaging, and Epigenetics Study – MiSBIE) of patients with m.3243A>G mutations, which included data on resting HR and BMI. *Cohort 6* [102] included data on circulating catecholamines at rest and during exercise. *Cohort 7* [85] included data on VO_2 during fixed workload (65W) and BMI. *Cohort 8* [103] included data on resting VO_2 and BMI. *Cohort 9* [104] included VO_2 during constant work rate (40% of max), and VO_2 values in ml/kg/min were adjusted to average workload achieved by each group to obtain comparable estimates of energetic demand relative to work performed. *Cohort 10* [14] included metabolic efficiency during constant-rate cycle ergometry (30 watts), including before and after a home-based exercise training protocol, and these values were compared to reference values in healthy individuals from [104]. *Cohort 11* [105] overlaps with Cohorts 9 and 10 and included BMI data. *Cohort 12* [17] included BMI data averaged between both mutation groups. *Cohort 13* [30] is a natural history study of adult patients with mortality data. *Cohort 14* [29] is a retrospective study of the causes of death in adult patients with mortality data. *Cohort 15* [106] is a pediatric natural history study with mortality data. *Cohort 16* [28] is a multi-center pediatric natural history study with mortality data. *Cohort 17* is an ongoing natural history study (McFarland et al., Newcastle Mitochondrial Disease Cohort) with mortality data.

Reference BMI for the USA (29.9 kg/m^2) was obtained from the National Health and Nutrition Examination Survey (NHANES) for wave 2015-2016 (n=9,544) (e-link), for the UK (28.6 kg/m^2) from the Health Survey for England 2018 (n=6,600) (link), and for Italy (25.8 kg/m^2) from the NCD Risk factor collaboration (link), with the combined average presented in Figure 1F. Reference values for life expectancy were obtained from the World Bank (https://data.worldbank.org/) and the average value for the USA (78.6 yr), UK (81.2 yr), and Italy (82.9 yr) (representing most cohorts included) is reported in Figure 1G. Data presented in Figure 1H represent mortality rates in the UK (reference population) for 2018, and the mortality data for individuals for mitochondrial disease was collected between 2010-2020.

The clinical data demonstrating hypermetabolism are derived from more than a dozen laboratories over a >15-year period, illustrating the stability of this finding. The apparent cross-study stability of clinical hypermetabolism is also unlikely to be influenced by publication or reporting bias for three main reasons: *i)* most studies were exploratory (as opposed to confirmatory) in nature, such that the motivation for their publication depended neither on the significance nor direction of these results, *ii)* baseline group differences for most parameters (e.g., resting VO_2) was not a primary outcome in any studies, and in several cases these data were not analyzed nor reported in the original reports, and *iii)* variables such as BMI are ubiquitously reported. Moreover, to further reduce the potential of bias, the overall sample includes new, previously unpublished cohorts of clinically and genetically well-defined patient populations (see Table 1). Together, these factors increase likelihood that the findings revealing the existence of a hypermetabolic state are robust and generalizable to mitochondrial diseases represented here, which includes a relatively broad diversity of mtDNA mutations. Further work directly quantifying hypermetabolism across the diurnal cycle, for example, are needed. Studies linking hypermetabolism to disease severity and progression are also warranted.

Skeletal muscle histology, mtDNA heteroplasmy, and mtDNA density

Human skeletal muscle from the diaphragm was subjected to sequential cytochrome c oxidase (COX, diaminobenzidine, brown) and succinate dehydrogenase (SDH, nitrobluetetrazolium, blue) staining as described previously [107]. This technique reveals segments of myofibers deficient for mtDNA-encoded COX but positive for exclusively nDNA-encoded SDH [22]. Sub-cellular segments of the same myofiber highlighted in Figure 1B were dissected from a 20um-thick cryosection by laser-capture microdissection (LCM) on a Leica AS LMD 6000 microscope, transferred and digested (Tween20, Proteinase K) overnight, and used as template DNA in a multiplex real-time PCR reaction that amplifies *MT-ND4* and *MT-ND1* amplicons within the minor and major arcs of the mtDNA, respectively, to calculate heteroplasmy levels for major arc mtDNA deletions [108]. Total mtDNA density was quantified by deriving *MT-ND1* copies from a standard curve, normalized per surface area (um^2) of tissue used as input [107].

Tissue culture

Primary human dermal fibroblasts were obtained from distributor or in local clinic from 3 healthy and 3 SURF1-patient donors (IRB #AAAB0483, see below table for descriptive information and distributor). Fibroblasts were isolated from skin tissue biopsies using standard procedures. After isolation, fibroblasts were stored in 10% DMSO (Sigma-Aldrich #D4540), 90% fetal bovine serum (FBS, Life Technologies #10437036) in cryogenic tube under liquid nitrogen. To avoid freeze-shock necrosis cells were frozen gradually in an isopropanol container (Thermofisher #5100-0001) at -80°C overnight before storage in liquid nitrogen.

Genotypes were confirmed by whole genome sequencing. Paired-end (PE) reads were obtained from Illumina HiSeq and processed using SAMtools (v1.2) and BaseSpace workflow (v7.0). PE reads were aligned to hg19 genome reference (UCSC) using Isaac aligner (v04.17.06.15) and BAM files were generated. Small variants including single nucleotide variants (SNVs) and insertion/deletion (Indels) were called from the entire genome using Strelka germline variant caller (v2.8). Variants specific to SURF1 gene were obtained from the genome-wide annotated vcf files using SnpSift and annotated using web ANNOVAR.

To initiate cultures, cryopreserved fibroblasts were thawed at 37°C (<4min) and immediately transferred to 20ml of preheated DMEM (Invitrogen #10567022). Cells were cultured in T175 flasks (Eppendorf #0030712129) at standard 5% CO_2 and atmospheric (~21%) O_2 at 37°C in DMEM (5.5 mM glucose) supplemented with 10% FBS, 50 µg/ml uridine (Sigma-Aldrich #U6381), 1% MEM non-essential amino acids (Life Technologies #11140050), 10 µM palmitate (Sigma-Aldrich #P9767) conjugated to 1.7 µM BSA (Sigma-Aldrich #A8806), and 0.001% DMSO (treatment-matched, Sigma-Aldrich #D4540). Cells were passaged approximately every 5 days (+/- 1 day). Oligo-treated healthy control cells were cultured in the same media as control cells supplemented with 1nM oligomycin (in 0.001% DMSO, Sigma-Aldrich #75351) starting on Day 15.

Brightfield microscopy images (10x, 20x magnification) were taken before each passaged using inverted phase-contrast microscope (Fisher Scientific #11350119). Cell counts, volume and death were determined at each passage using the Countess II Automated Cell Counter (ThermoFisher Scientific #A27977). Growth rates were used to determine replating density, by pre-calculating number of cells needed to reach ~90% confluency (~2.5 million cells) at time of next passage. Cells were never plated below 200,000 cells or above 2.5 million cells to avoid plating artifacts of isolation or contact inhibition, respectively. The timing and frequency of time points collected vary by assay, with an average sampling frequency of 15 days[109]. Cell media was collected at each passage. Individual cell lines were terminated after exhibiting less than one population doubling over a 30-day period. The Hayflick limit was determined as the total number of population doublings of a cell line at the point of termination.

Because oxygen tension can have a marked effect on the metabolism and replicative lifespan of cultured fibroblasts [110], and chronic hypoxia improves survival in fibroblasts with complex I defects and the Ndufs4 mouse model of Leigh syndrome [111], longitudinal experiments in SURF1 cells were repeated at low (3%) O_2, in parallel with the same donor cell lines at atmospheric O_2 (~21%). Oxygen levels did not prevent or alter hypermetabolism, nor did they improve cell population growth rate (data not shown). Results of the low O_2 "hypoxia" experiments as well as the full lifespan aging trajectory of control cells beyond 150 days are available in the resource dataset (see *Data Availability Statement*).

Extended Data Table 1. Control and SURF1 donor characteristics

Cell Line	Tissue	Genotype	Sex	Age	Passage*	Source	Cat #
Donor 1	Dermal breast	Normal	male	18	1	Lifeline Cell Technology	FC-0024 Lot # 03099
Donor 2	Dermal breast	Normal	female	18	1	Lifeline Cell Technology	FC-0024 Lot # 00967
Donor 3	Foreskin	Normal	male	0	4	Coriell Institute	AG01439
Patient 1	Dermal upper-arm skin	*SURF1* mutation	male	0.25	7	Hirano lab	NA
Patient 2	Dermal upper-arm skin	*SURF1* mutation	male	11	5	Hirano lab	NA
Patient 3	Dermal upper-arm skin	*SURF1* mutation	female	9	9	Hirano lab	NA

**Passage indicates the passage at which cells were obtained before experiment began.*

Extended Data Table 2. Genotyping results of SURF1 patient-derived fibroblasts

Cell line	Surf1 mutation	Exonic function	dbSNP id	Clinical significance*
Patient 1	c.518_519del (p.S173Cfs*7) c.845_846del (p.S282Cfs*7)	frameshift deletion	rs782316919	Pathogenic | Pathogenic
Patient 2	c.247_248insCTGC (p.R83Pfs*7) c.574_575insCTGC (p.R192Pfs*7)	frameshift insertion	rs782289759	NA
	c.C246G (p.T82T) C573G (p.T191T)	synonymous SNV	rs28715079	Benign | Likely Benign
	c.313_321del (p.L105_A107del)	nonframeshift deletion	rs759270179	NA
	c.311_312insA (p.L105Sfs*11)	frameshift insertion	rs764928653	NA
	c.T280C (p.L94L)	synonymous SNV	rs28615629	Benign | Likely Benign
Patient 3	c.C246G (p.T82T) c.C573G (p.T191T)	synonymous SNV	rs28715079	Benign | Likely Benign
	Homozygous c.313_321del (p.L105_A107del)	nonframeshift deletion	rs759270179	NA
	c.T280C (p.L94L)	synonymous SNV	rs28615629	Benign | Likely Benign

*Results from whole genome sequencing (WGS). * Clinical interpretation of genetic variants is based on ANNOVAR gene annotation pipeline that uses ClinVar database as a primary reference. SNV, single nucleotide variant.*

Mycoplasma testing

Mycoplasma testing was performed according to the manufacturer's instructions (R&D Systems #CUL001B) at the end of lifespan for each treatment and cell line used. All tests were negative.

Calculations of energy expenditure and normalization to division rate and cell size

Bioenergetic parameters were measured using the XFe96 Seahorse extracellular flux analyzer (Agilent), oxygen consumption rate (OCR) and extracellular acidification rate (pH change) was measured over confluent cell monolayers. Cells were plated for Seahorse measurement every 3 passages (~15 days) with 10-12 wells plated per a treatment group. Each well of a seahorse 96-well plate was plated with 20,000 cells and incubated overnight under standard growth conditions, following the manufacturer's instructions, including a plate wash with complete Seahorse XF Assay media. The complete XF media contains no pH buffers and was supplemented with 5.5 mM glucose, 1 mM pyruvate, 1 mM glutamine, 50 µg/ml uridine, 10 µM palmitate conjugated to 1.7 µM BSA. After washing, the plate was incubated in a non-CO_2 incubator for one hour to equilibrate temperature and atmospheric gases. The instrument was programmed to assess various respiratory states using the manufacturer's MitoStress Test (Brand & Nicholls, 2011). Basal respiration, ATP turnover, proton leak, coupling efficiency, maximum respiration rate, respiratory control ratio, spare respiratory capacity and non-mitochondrial respiration were all determined by the sequential additions of the ATP synthase inhibitor oligomycin (final concentration: 1 µM), the protonophore uncoupler FCCP (4 µM), and the electron transport chain Complex I and III inhibitors, rotenone and antimycin A (1 µM). The optimal number of cells and concentration for the uncoupler FCCP yielding maximal uncoupled respiration was determined based on a titration performed on healthy fibroblasts (data not shown).

The final Seahorse injection included Hoechst nuclear fluorescent stain (ThermoFisher Scientific #62249) to allow for automatic cell counting. After each run, cell nuclei were counted automatically using the Cytation1 Cell Imager (BioTek) and raw bioenergetic measurements were normalized to relative cell counts on a per-well basis. ATP metrics were determined using the P/O ratios of OxPhos and glycolysis as previously described by Mookerjee et al. [55]. These conversions assumed energy sourced was derived entirely by glucose. All J_{ATP} measurements take into account non-mitochondrial and proton leak derived oxygen consumption thereby reflecting the mitochondrial ATP-synthesis related flux (**Extended Data Figure 2A**). The code and raw data are available as detailed in the Data Availability statement.

To assess if increased ECAR in experimental conditions were due to non-glycolytic activity, a glucose-dependency test was performed using the Seahorse XF Glycolysis Stress Test Kit (Agilent, 103020-100). Prior to extracellular flux measurements, young healthy control (Donor2) and young SURF1 (Patient3) cells were grown overnight in differing nutrient conditions: physiological 5.5mM glucose, 0mM glucose, 25mM glucose. The glycolysis stress test kit was performed according to the manufacturer's protocol. To monitor growth and cell death, cells were cultured for 7 days in each glucose condition and monitored daily (see Extended Data Figure 3).

mtDNA deletions

mtDNA deletions were initially detected by long-range PCR (LR-PCR) from DNA extracted from cultured fibroblasts using DNeasy blood and tissue kit (Qiagen #69504) following manufacturer's instructions. Isolated DNA was amplified using 12 F (np 5855-5875) and D2 R (np 129-110) oligonucleotide primers to yield a 10-Kb product. PCR reactions were carried out using Hot Start TaKaRa LA Taq kit (Takara Biotechnology, #RR042A) with the following cycling conditions: 1 cycle of 94°C for 1min; 45 cycles of 94°C for 30sec, 58°C for 30sec, and 68°C for 11min with a final extension of 72°C for 12 min. Amplified PCR products were separated on 1% agarose gels in 1X TBE buffer, stained with GelGreen (Biotium #41005), imaged using a GelDoc Go Imager (Biorad). Primers (5'-3') were: Forward (12F): AGATTTACAGTCCAATGCTTC (nucleotide position 5,855-5,875); Reverse (D2R): AGATACTGCGACATAGGGTG (129-110).

mtDNA next-generation sequencing and eKLIPse analysis

The entire mtDNA was amplified in two overlapping fragments using a combination of mtDNA primers. The primer pairs used for PCR amplicons were tested first on Rho zero cells devoid of mtDNA to remove nuclear-encoded mitochondrial pseudogene (NUMTS) amplification (PCR1: 5'-AACCAAACCCCAAAGACACC-3' and 5'-GCCAATAATGACGTGAAGTCC-3'; PCR2: 5'-TCCCACTCCTAAACACATCC-3' and 5'-TTTATGGGGTGATGTGAGCC-3'). Long-range PCR was performed with the Kapa Long Range DNA polymerase according to the manufacturer's recommendations (Kapa Biosystems, Boston, MA, mtDNA next-generation sequencing and USA), with 0.5μM of each primer and 20ng of DNA. The PCR products were analyzed on a 1% agarose gel electrophoresis.

NGS Libraries were generated using an enzymatic DNA fragmentation approach using Ion Xpress Plus Fragment Library Kit. Libraries were diluted at 100 pM before sequencing and pooled by a maximum of 25 samples. Sequencing was performed using an Ion Torrent S5XL platform using Ion 540 chipTM. Signal processing and base calling were done by the pre-processing embedded pipeline. Demultiplexed reads were mapped according to the mtDNA reference sequence (NC_012920.1) before

being analysed with a dedicated homemade pipeline including eKLIPse (Goudenège et al, GIM, 2019; https://github.com/dooguypapua/eKLIPse) using the following settings:

- Read threshold: min Quality=20 | min length =100bp
- Soft-Clipping threshold: Read threshold: Min soft-clipped length =25pb | Min mapped Part=20 bp
- BLAST thresholds: min=1 | id=80 | cov=70 | gapopen=0 | gapext=2
- Downsampling: No

mtDNA copy number

Cellular mtDNA content was quantified by qPCR on the same genomic material used for other DNA-based measurements. Duplex qPCR reactions with Taqman chemistry were used to simultaneously quantify mitochondrial (mtDNA, ND1) and nuclear (nDNA, B2M) amplicons, as described previously [4]. The reaction mixture included TaqMan Universal Master mix fast (life technologies #4444964), 300nM of custom design primers and 100nM probes: ND1-Fwd: GAGCGATGGTGAGAGCTAAGGT, ND1-Rev:CCCTAAAACCCGCCACATCT, ND1-Probe: HEX-CCATCACCCTCTACATCACCGCCC-3IABkFQ. B2M-Fwd: CCAGCAGAGAATGGAAAGTCAA, B2M-Rev: TCTCTCTCCATTCTTCAGTAAGTCAACT, B2M-Probe: FAM-ATGTGTCTGGGTTTCATCCATCCGACA-3IABkFQ). The samples were cycled in a QuantStudio 7 flex qPCR instrument (Applied Biosystems) at 50°C for 2 min, 95°C for 20 sec, 95°C for 1min, 60°C for 20 sec, for 40 cycles. qPCR reactions were setup in triplicates in 384 well qPCR plates using a liquid handling station (epMotion5073, Eppendorf), in volumes of 20ul (12ul mastermix, 8ul template). Triplicate values for each sample were averaged for mtDNA and nDNA. Ct values >33 were discarded. For triplicates with a C.V. > 0.02, the triplicates were individually examined and outlier values removed where appropriate (e.g., >2 standard deviations above the mean), with the remaining duplicates were used. The final cutoff for acceptable values was set at a C.V. = 0.1 (10%); samples with a C.V. > 0.1 were discarded. A standard curve along with positive and negative controls were included on each of the seven plates to assess plate-to-plate variability and ensure that values fell within instrument range. The final mtDNAcn was derived using the ΔCt method, calculated by subtracting the average mtDNA Ct from the average nDNA Ct. mtDNAcn was calculated as $2^{\Delta Ct}$ x 2 (to account for the diploid nature of the reference nuclear genome), yielding the estimated number of mtDNA copies per cell.

Cytokines

Two multiplex fluorescence-based arrays were custom-designed with selected cytokines and chemokines most highly correlated with age in human plasma from [63], listed as available analytes on the R&D custom Luminex arrays (R&D, Luminex Human Discovery Assay (33-Plex) LXSAHM-33 and LXSAHM-15, http://biotechne.com/l/rl/YyZYM7n3). Media samples were collected at selected passages across cellular lifespan and frozen at -80°C. After thawing, samples were centrifuged at 500xg for 5min

and supernatant moved to a new tube. Wells were loaded with media samples diluted 1:5 with assay diluent, incubated, washed, and read on a Luminex 200 (Luminex, USA) as per the manufacturer's instructions. Positive (aged healthy fibroblast) and negative controls (fresh untreated media) samples were used in duplicates on each plate to quantify batch variations. Data were fitted and final values interpolated from a standard curve in xPONENT v 4.2, normalized to the cell number at the time of collection to produce estimates of cytokine production on a per-cell basis. IL-6 and GDF15 measures were repeated using enzyme-linked immunosorbent assays (ELISA), according to the manufacturer's instructions (Abcam #ab229434 and R&D #DGD150).

Media cell-free DNA

Total cell-free DNA (cf-DNA) was isolated from cell culture media using a previously published automated, high throughput methodology (Ware et al. 2020). Quantitative polymerase chain reaction (qPCR): cf-mtDNA and cf-nDNA levels were measured simultaneously by qPCR. Taqman-based duplex qPCR reactions targeted mitochondrial-encoded ND1 and nuclear-encoded B2M sequences as described previously [112,113]. Each gene assay contained two primers and a fluorescent probe and were assembled as a 20X working solution according to the manufacturer's recommendations (Integrated DNA Technologies). The assay sequences are: ND1 forward 5'-GAGCGATGGTGAGAGCTAAGGT-3', ND1 reverse 5'-CCCTAAAACCCGCCACATCT-3', ND1 probe 5'-/5HEX/CCATCACCC/ZEN/TCTACATCACCGCCC/2IABkGQ/-3', B2M forward 5'-TCTCTCTCCATTCTTCAGTAAGTCAACT-3', B2M reverse 5'-CCAGCAGAGAATGGAAAGTCAA-3', and B2M probe 5'-/56-FAM/ATGTGTCTG/ZEN/GGTTTCATCCATCCGACCA/3IABkFQ/-3'. Each reaction contained 4 µL of 2X Luna Universal qPCR Master Mix (New England Biolabs, cat#M3003E), 0.4 µL of each 20X primer assay, and 3.2 µL of template cf-DNA for a final volume of 8 µL. The qPCR reactions were performed in triplicates using a QuantStudio 5 Real-time PCR System (Thermo Fisher, cat#A34322) using the following thermocycling conditions: 95°C for 20 s followed by 40 cycles of 95°C for 1 s, 63°C for 20 s, and 60°C for 20 s. Serial dilutions of pooled human placenta DNA were used as a standard curve.

Digital PCR (dPCR): mtDNA and nDNA copy number (copies/µL) of the standard curve used in cf-mtDNA/cf-nDNA assessment were measured separately using singleplex ND1 and B2M assays using a QuantStudio 3D Digital PCR System and associated reagents (Thermo Fisher, cat#A29154) according to the manufacturer's protocol. The values obtained for the standard curve were used to calculate the copy number for the experimental samples. All reactions were performed in duplicate (two chips). Because the same standard curve was used on all plates, its copy number was applied uniformly to all qPCR plates.

RNA sequencing and transcriptomic analyses

Total genomic RNA was isolated every ~11days across cellular lifespan and stored in 1ml TRIzol (Invitrogen #15596026). RNA was extracted on-column using the RNeasy kit (Qiagen #74104), DNase treated according to the manufacturer's instructions, and quantified using the QUBIT high sensitivity kit (Thermo Fisher Scientific #Q32852). RNA samples underwent QC on bioanalyzer and Nanodrop 2000, all samples had a RIN score >8.0 and no detectable levels of DNA. RNA (1500ng/sample, 50ng/µl) was then submitted for sequencing at Genewiz Inc. (Illumina HiSeq, single index, 10 samples/lane), and underwent RiboZero Gold purification. Sequenced reads yielding approximately 40 million paired-end 150bp single-end reads per sample. Sequenced reads were then aligned using the pseudoalignment tool, kallisto v0.44.0 [114]. These data were imported using txi import ('tximport', v1.18.0, length-scaled TPM), and vst normalized ('DEseq2', v1.30.1).

Dimensionality reduction was performed using 'Rtsne' v0.15 with perplexity value of 10 and initial dimensions of 30 on the log2 transformed normalized expression values after removing genes without any variation in expression across all samples. Linear mixed modeling was performed using the 'lme4' v1.1 r package with the fixed effects of time grown and clinical group for SURF1-differential expression and fixed effects of time grown and treatment with a mixed effects of the cell line for Oligo-differential expression. P values were obtained by running an Anova comparing the model for each gene to a null model that had a fixed effect of days grown (mixed effects of cell line for Oligo models) and then the value was corrected for multiple comparisons using FDR-adjustment ($p<0.05$). We used iPAGE to discover perturbed pathways in SURF1 and Oligo-treated cells (https://tavazoielab.c2b2.columbia.edu/iPAGE/) [71]. iPAGE enables the systematic and comprehensive discovery of pathways that are significantly informative of gene expression measurements without any explicit thresholding requirements. Additionally, iPAGE is also able to detect pathways whose constituent genes are both up- and down-regulated in the treatments. Input to iPAGE included gene symbols and for each gene, a cluster identifier indicating if it was upregulated, downregulated or not differentially expressed in both (i.e. intersection) SURF1-mutant and Oligo-treated cells compared to controls. For discovering significantly over- and under-represented pathways using iPAGE, we used a stringent p value cutoff of 0.001 along with minr=1, ind=0 (to produce the most expansive set of pathway terms) and, catMin=30 (to exclude pathways with fewer than 30 genes). Timecourse and heatmaps show transcript levels relative to the median of the youngest control timepoints. Categorized genes were selected based on known mitochondrial and aging literature. Categorized pathways were categorized into meta-categories based on shared gene ontology parent processes.

DNA methylation and methylome analysis

Global DNA methylation was measured using the Illumina EPIC microarray ran at the UCLA Neuroscience Genomic Core (UNGC). DNA was extracted using the DNeasy kit (Qiagen cat#69506) according to the manufacturer's protocol and quantified using QUBIT broad range kit (Thermo Fisher

Scientific cat#Q32852). At least 375 ng of DNA was submitted in 30 µl of ddH_2O to UNGC for bisulfite conversion and hybridization using the Infinium Methylation EPIC BeadChip kit. Sample positions across plates were randomized to avoid batch variation effects on group or time-based comparisons. All DNA methylation data were processed in R (v4.0.2), using the 'minfi' package (v1.36.0). Quality control preprocessing was applied by checking for correct sex prediction, probe quality, sample intensities, and excluding SNPs and non-CpG probes. Data were then normalized using Functional Normalization. Using the R package 'sva' (v3.12.0), both RCP and ComBat adjustments were applied to correct for probe-type and plate bias, respectively. After quality control, DNAm levels were quantified for 865,817 CpG Sites.

Dimensionality reduction was performed using the 'Rtsne' package (v0.15) with a perplexity value of 10 and initial dimensions of 30 on the normalized beta values. We ran linear mixed effects models (LMER) using 'lme4' v1.1. For our differential methylation analysis of SURF1, the fixed effects were assigned to '*days_grown'* and '*clinical_group'*. For the Oligomycin treatment, the fixed effects '*time_grown'* and '*treatment'* and the mixed effect was assigned of the '*cell_lines'* (i.e., donors). P values were obtained from an analysis of variance (ANOVA) comparing the model for each CpG to a null model with a fixed effect of days grown (mixed effects of cell line for Oligomycin models) and then corrected for multiple comparisons using FDR-adjustment ($p < 0.05$) to identify differentially methylated CpGs (DMPs). Differentially methylated regions (DMRs) were derived using the modified comb-p method in the 'Enmix' package (v1.26.8), with a maximum distance for DMR combination of 1000bp, a bin size for autocorrelation of 310, and FDR-adjustment cutoff of 0.01, and minimum of 3 CpGs per a DMR. Each DMP and DMR were assigned to the nearest annotated gene (IlluminaHumanMethylationEPICanno.ilm10b4.hg19 package, v0.6.0). Gene set enrichment analysis was then performed using ShinyGO [115] (v0.66, http://bioinformatics.sdstate.edu/go/) on the top 1,000 DMPs- or DMRs-associated genes based on the combined negative log p value across hyper- and hypo-methylated DMPs and DMRs.

Relative telomere length

Relative telomere length was measured by quantitative polymerase chain reaction (qPCR), expressed as the ratio of telomere to single-copy gene abundance (T/S ratio). The telomere length measurement assay was adapted from the published original method by Cawthon [116,117]. The telomere thermal cycling profile consisted of: Cycling for T(celomic) PCR: Denature at 96°C for 1 minute, one cycle; denature at 96°C for 1 second, anneal/extend at 54°C for 60 seconds, with fluorescence data collection, 30 cycles. Cycling for S (single copy gene) PCR: Denature at 96°C for 1 minute, one cycle; denature at 95°C for 15 seconds, anneal at 58°C for 1 second, extend at 72°C for 20 seconds, 8 cycles; followed by denature at 96°C for 1 second, anneal at 58°C for 1 second, extend at 72°C for 20 seconds, hold at 83°C for 5 seconds with data collection, 35 cycles. The primers for the telomere PCR are tel1b

[5'-CGGTTT(GTTTGG)$_5$GTT-3'], used at a final concentration of 100 nM, and tel2b [5'-GGCTTG(CCTTAC)$_5$CCT-3'], used at a final concentration of 900 nM. The primers for the single-copy gene (human beta-globin) PCR are hbg1 [5' GCTTCTGACACAACTGTGTTCACTAGC-3'], used at a final concentration of 300 nM, and hbg2 [5'-CACCAACTTCATCCACGTTCACC-3'], used at a final concentration of 700 nM. The final reaction mix contained 20 mM Tris-HCl, pH 8.4; 50 mM KCl; 200 μM each dNTP; 1% DMSO; 0.4x SYBR Green I; 22 ng E. coli DNA; 0.4 Units of Platinum Taq DNA polymerase (Invitrogen Inc.); approximately 6.6 ng of genomic DNA per 11 microliter reaction. Tubes containing 26, 8.75, 2.9, 0.97, 0.324 and 0.108ng of a reference DNA (Human genomic DNA from buffy coat, Sigma cat# 11691112001) are included in each PCR run so that the quantity of targeted templates in each research sample can be determined relative to the reference DNA sample by the standard curve method. The same reference DNA was used for all PCR runs. Assays were run in triplicate wells on 384-well assay plates in a Roche LightCycler 480. The average concentrations of T and S from the triplicate wells were used to calculate the T/S ratios after a Dixon's Q test to remove outlier wells from the triplicates. T/S ratio for each sample was measured twice. When the duplicate T/S value and the initial value varied by more than 7%, the sample was run the third time and the two closest values were reported. 26 out of the 512 samples (5%) has a CV greater than 10% after the third measurement. The inter-assay coefficient of variation (CV) for this study is 3.0%±4.3% (including the 26 samples) and 2.2%±2.0% (excluding the 26 samples). Telomere length assay for the entire study were performed using the same lots of reagents. Lab personnel lab who performed the assays were provided with de-identified samples and were blind to other data.

DNAmAge

DNAmAge was calculated using the online calculator (https://dnamage.genetics.ucla.edu/new) with normalization using the age of cell line donor as the input age. This outputted the Horvath1 (i.e. PanTissue clock), Horvath2 (Skin&Blood clock), PhenoAge, Hannum, and GrimAge estimated DNAmAges. PC-based DNAmAges were then obtained using the principal component method [80]. The rates of epigenetic aging for each cell line were determined from the linear slope of timepoints between 25 to 75 days. This period ensures that Oligo treatment has taken effect, and avoids late-life changes in the behavior of DNAm clocks, providing the time window where the signal is most stable.

Data analysis and statistics

All statistical analyses were performed using GraphPad Prism (v9.0) and RStudio (v1.3.1056) using R (v4.0.2). Comparisons of groups between control, SURF1 and treatment groups were performed using mixed effects model, except for peak and rate measurements (unpaired T-test, assuming unequal variance or two-way ANOVA for concurrent measures). Interpolated curves for each experimental group is the best fit non-linear third order or fifth order polynomial functions depending on

the kinetic complexity a given measurement. Data visualization and statistical analyses were generated in R (ggplot2) and Prism 8.

The time windows for specific statistical analyses were selected based on a combination of cellular growth behavior including: i) population doubling curves (e.g., stable division rates for all groups early in the cellular lifespan between days 20-50), ii) the availability of matching timepoints between treatment groups (at least 3 timepoints for all groups), and iii) potential delay to reach stable cellular phenotypes in Oligo-treated cells. To allow for adjustment to the *in vitro* environment, treatments began after 15 days of culture. Therefore, overall "lifespan effects" were determined between 20-150 days, which represents the maximal replicative lifespan of SURF1 cells. "Early life" effects that isolate most clearly the effects of OxPhos dysfunction, and avoid the potential accelerated aging phenotypes in SURF1 and Oligo cells, were examined using timepoints between 20-50 days. For analyses of differentially expressed genes (RNASeq, Figure 6) and differential methylation (DNAm, Figure 7) where a greater datapoint density was necessary to achieve robust mixed effects models, SURF1 cells were analyzed between 0 and 75 days (genetic defects in *SURF1* are constitutive so do not require time in culture to manifest) whereas models for Oligo-treated cells used timepoints between days 35 to 110 (allowing 15 days for the effects of ATP synthase inhibition to manifest in the transcriptome, while avoiding late-life changes). All timepoints are shown in time series graphs.

Supplementary Material

Extended Data Figures 1-12, Extended Data Table 1-2, and Supplemental Files 1-10 are available in the online supplement to this article.

Author contributions

G.S. and M.P. designed experiments. M.H. provided cell lines. G.S. performed cellular studies and processed samples with assistance from A.S.M and A.T. G.S. analyzed data with assistance from A.S.M., B.S.S. and A.C. K.R.K. performed long-range PCR, cytokine arrays, and WGS analysis. S.A.D. and B.K. measured cf-mtDNA. J.L. and E.S.E. measured telomere length. A.H.C., M.L., and S.H. contributed epigenetic clocks. B.S.S. and S.T. performed the iPAGE analyses. C.B., V.P., G.L. performed mtDNA sequencing. T.T., S.R., R.S., V.K.M., B.G., R.K.M., R.H. provided data for the meta-analysis of clinical data. M.P., G.S., M.H., and E.L.S. drafted the manuscript. All authors reviewed the final version of the manuscript.

Acknowledgements

We are grateful to Jane Newman, Renae Stefanetti, Robert McFarland, Robert Taylor, and Grainne S Gorman (Wellcome Center for Mitochondrial Research), Rohit Sharma and Vamsi Mootha (Massachusetts General Hospital), and other investigators whose work contributed to the meta-analysis in Figure 1; and to Marlon McGill for technical assistance with parts of this project. The cellular studies were supported by NIH grant AG066828 to M.P., the J. Willard and Alice S. Marriott Foundation, Muscular Dystrophy Association, Nicholas Nunno Foundation, JDF Fund for Mitochondrial Research, and Shuman Mitochondrial Disease Fund to MH. All research at Great Ormond Street Hospital NHS Foundation Trust and UCL Great Ormond Street Institute of Child Health is made possible by the NIHR Great Ormond Street Hospital Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Data availability statement

The complete dataset for the present study is available without restriction and can be accessed, visualized, and downloaded using our webtool: https://columbia-picard.shinyapps.io/shinyapp-Lifespan_Study/. Data presented in this manuscript was generated as part of the *Cellular Lifespan Study*, which includes metabolic and endocrine experimental treatments across multiple donors described in detail in [109]. The RNAseq and DNA methylation datasets for this project are available under the GEO SuperSeries GSE179849. All data preprocessing and analysis code is available on GitHub (https://github.com/gav-sturm/Cellular_Lifespan_Study).

Conflict of interests

The authors have no conflict of interest to declare.

References

1. Gorman, G.S., *et al.* Mitochondrial diseases. *Nat Rev Dis Primers* **2**, 16080 (2016).
2. Rossignol, R., *et al.* Mitochondrial threshold effects. *Biochem J* **370**, 751-762 (2003).
3. Mick, E., *et al.* Distinct mitochondrial defects trigger the integrated stress response depending on the metabolic state of the cell. *eLife* **9**(2020).
4. Picard, M., *et al.* Progressive increase in mtDNA 3243A>G heteroplasmy causes abrupt transcriptional reprogramming. *Proc Natl Acad Sci U S A* **111**, E4033-4042 (2014).
5. Quiros, P.M., *et al.* Multi-omics analysis identifies ATF4 as a key regulator of the mitochondrial stress response in mammals. *J Cell Biol* **216**, 2027-2045 (2017).
6. Khan, N.A., *et al.* mTORC1 Regulates Mitochondrial Integrated Stress Response and Mitochondrial Myopathy Progression. *Cell Metab* **26**, 419-428 e415 (2017).
7. Kuhl, I., *et al.* Transcriptomic and proteomic landscape of mitochondrial dysfunction reveals secondary coenzyme Q deficiency in mammals. *eLife* **6**(2017).
8. Kaspar, S., *et al.* Adaptation to mitochondrial stress requires CHOP-directed tuning of ISR. *Sci Adv* **7**(2021).
9. Forsstrom, S., *et al.* Fibroblast Growth Factor 21 Drives Dynamics of Local and Systemic Stress Responses in Mitochondrial Myopathy with mtDNA Deletions. *Cell Metab* **30**, 1040-1054 e1047 (2019).
10. Chung, H.K., *et al.* Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. *J Cell Biol* **216**, 149-165 (2017).
11. Suomalainen, A. & Battersby, B.J. Mitochondrial diseases: the contribution of organelle stress responses to pathology. *Nat Rev Mol Cell Biol* **19**, 77-92 (2018).
12. Gorman, G.S., *et al.* Perceived fatigue is highly prevalent and debilitating in patients with mitochondrial disease. *Neuromuscul Disord* **25**, 563-566 (2015).
13. Kaufmann, P., *et al.* Protean phenotypic features of the A3243G mitochondrial DNA mutation. *Arch Neurol* **66**, 85-91 (2009).
14. Porcelli, S., Marzorati, M., Morandi, L. & Grassi, B. Home-based aerobic exercise training improves skeletal muscle oxidative metabolism in patients with metabolic myopathies. *J Appl Physiol (1985)* **121**, 699-708 (2016).
15. Apabhai, S., *et al.* Habitual physical activity in mitochondrial disease. *PLoS One* **6**, e22294 (2011).
16. Lowell, B.B. & Shulman, G.I. Mitochondrial dysfunction and type 2 diabetes. *Science* **307**, 384-387 (2005).
17. Hou, Y., *et al.* Appendicular skeletal muscle mass: A more sensitive biomarker of disease severity than BMI in adults with mitochondrial diseases. *PLoS One* **14**, e0219628 (2019).
18. Makarieva, A.M., *et al.* Mean mass-specific metabolic rates are strikingly similar across life's major domains: Evidence for life's metabolic optimum. *Proc Natl Acad Sci U S A* **105**, 16994-16999 (2008).

19. Basan, M., *et al.* Overflow metabolism in Escherichia coli results from efficient proteome allocation. *Nature* **528**, 99-104 (2015).

20. Buttgereit, F. & Brand, M.D. A hierarchy of ATP-consuming processes in mammalian cells. *Biochem J* **312 (Pt 1)**, 163-167 (1995).

21. Kafri, M., Metzl-Raz, E., Jona, G. & Barkai, N. The Cost of Protein Production. *Cell Rep* **14**, 22-31 (2016).

22. Vincent, A.E. & Picard, M. Multilevel heterogeneity of mitochondrial respiratory chain deficiency. *J Pathol* **246**, 261-265 (2018).

23. Hoitzing, H., *et al.* Energetic costs of cellular and therapeutic control of stochastic mitochondrial DNA populations. *PLoS Comput Biol* **15**, e1007023 (2019).

24. Becker, C., *et al.* CLPP deficiency protects against metabolic syndrome but hinders adaptive thermogenesis. *EMBO Rep* **19**(2018).

25. Morrow, R.M., *et al.* Mitochondrial energy deficiency leads to hyperproliferation of skeletal muscle mitochondria and enhanced insulin sensitivity. *Proc Natl Acad Sci U S A* **114**, 2705-2710 (2017).

26. Celotto, A.M., Chiu, W.K., Van Voorhies, W. & Palladino, M.J. Modes of metabolic compensation during mitochondrial disease using the Drosophila model of ATP6 dysfunction. *PLoS One* **6**, e25823 (2011).

27. Agostino, A., *et al.* Constitutive knockout of Surf1 is associated with high embryonic lethality, mitochondrial disease and cytochrome c oxidase deficiency in mice. *Hum Mol Genet* **12**, 399-413 (2003).

28. Wedatilake, Y., *et al.* SURF1 deficiency: a multi-centre natural history study. *Orphanet J Rare Dis* **8**, 96 (2013).

29. Barends, M., *et al.* Causes of Death in Adults with Mitochondrial Disease. *JIMD reports* **26**, 103-113 (2016).

30. Kaufmann, P., *et al.* Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype. *Neurology* **77**, 1965-1971 (2011).

31. Keshavan, N. & Rahman, S. Natural history of mitochondrial disorders: a systematic review. *Essays Biochem* **62**, 423-442 (2018).

32. Trifunovic, A., *et al.* Premature ageing in mice expressing defective mitochondrial DNA polymerase. *Nature* **429**, 417-423 (2004).

33. Kujoth, G.C., *et al.* Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. *Science* **309**, 481-484 (2005).

34. Quintana, A., Kruse, S.E., Kapur, R.P., Sanz, E. & Palmiter, R.D. Complex I deficiency due to loss of Ndufs4 in the brain results in progressive encephalopathy resembling Leigh syndrome. *Proc Natl Acad Sci U S A* **107**, 10996-11001 (2010).

35. Quadalti, C., *et al.* SURF1 knockout cloned pigs: Early onset of a severe lethal phenotype. *Biochim Biophys Acta Mol Basis Dis* **1864**, 2131-2142 (2018).

36. Schrack, J.A., Knuth, N.D., Simonsick, E.M. & Ferrucci, L. "IDEAL" aging is associated with lower resting metabolic rate: the Baltimore Longitudinal Study of Aging. *J Am Geriatr Soc* **62**, 667-672 (2014).

37. Jumpertz, R.*, et al.* Higher energy expenditure in humans predicts natural mortality. *J Clin Endocrinol Metab* **96**, E972-976 (2011).

38. Ruggiero, C.*, et al.* High basal metabolic rate is a risk factor for mortality: the Baltimore Longitudinal Study of Aging. *J Gerontol A Biol Sci Med Sci* **63**, 698-706 (2008).

39. Tencerova, M.*, et al.* Obesity-Associated Hypermetabolism and Accelerated Senescence of Bone Marrow Stromal Stem Cells Suggest a Potential Mechanism for Bone Fragility. *Cell Rep* **27**, 2050-2062 e2056 (2019).

40. Molenaar, D., van Berlo, R., de Ridder, D. & Teusink, B. Shifts in growth strategies reflect tradeoffs in cellular economics. *Mol Syst Biol* **5**, 323 (2009).

41. Yang, X.*, et al.* Physical bioenergetics: Energy fluxes, budgets, and constraints in cells. *Proc Natl Acad Sci U S A* **118**(2021).

42. Takauji, Y.*, et al.* Restriction of protein synthesis abolishes senescence features at cellular and organismal levels. *Scientific reports* **6**, 18722 (2016).

43. Takauji, Y., En, A., Miki, K., Ayusawa, D. & Fujii, M. Combinatorial effects of continuous protein synthesis, ERK-signaling, and reactive oxygen species on induction of cellular senescence. *Exp Cell Res* **345**, 239-246 (2016).

44. Moraes, C.T.*, et al.* Molecular analysis of the muscle pathology associated with mitochondrial DNA deletions. *Nat Genet* **1**, 359-367 (1992).

45. Yu-Wai-Man, P.*, et al.* OPA1 mutations cause cytochrome c oxidase deficiency due to loss of wild-type mtDNA molecules. *Hum Mol Genet* **19**, 3043-3052 (2010).

46. Lehmann, D.*, et al.* Understanding mitochondrial DNA maintenance disorders at the single muscle fibre level. *Nucleic Acids Res* **47**, 7430-7443 (2019).

47. Vincent, A.E.*, et al.* Subcellular origin of mitochondrial DNA deletions in human skeletal muscle. *Ann Neurol* **84**, 289-301 (2018).

48. Green, J.A. The heart rate method for estimating metabolic rate: review and recommendations. *Comp Biochem Physiol A Mol Integr Physiol* **158**, 287-304 (2011).

49. Vissing, J., Galbo, H. & Haller, R.G. Exercise fuel mobilization in mitochondrial myopathy: a metabolic dilemma. *Ann Neurol* **40**, 655-662 (1996).

50. Ratheiser, K.M., Brillon, D.J., Campbell, R.G. & Matthews, D.E. Epinephrine produces a prolonged elevation in metabolic rate in humans. *Am J Clin Nutr* **68**, 1046-1052 (1998).

51. Tiranti, V.*, et al.* Mutations of SURF-1 in Leigh disease associated with cytochrome c oxidase deficiency. *Am J Hum Genet* **63**, 1609-1621 (1998).

52. Hayflick, L. & Moorhead, P.S. The serial cultivation of human diploid cell strains. *Exp Cell Res* **25**, 585-621 (1961).

53. Sturm, G.*, et al.* Human aging DNA methylation signatures are conserved but accelerated in cultured fibroblasts. *Epigenetics* **14**, 961-976 (2019).

54. Brydges, C.R. Effect Size Guidelines, Sample Size Calculations, and Statistical Power in Gerontology. *Innov Aging* **3**, igz036 (2019).

55. Mookerjee, S.A., Gerencser, A.A., Nicholls, D.G. & Brand, M.D. Quantifying intracellular rates of glycolytic and oxidative ATP production and consumption using extracellular flux measurements. *J Biol Chem* **292**, 7189-7207 (2017).

56. Schmidt, C.A., Fisher-Wellman, K.H. & Neufer, P.D. From OCR and ECAR to energy: Perspectives on the design and interpretation of bioenergetics studies. *J Biol Chem* **297**, 101140 (2021).

57. Guo, X.*, et al.* Mitochondrial stress is relayed to the cytosol by an OMA1-DELE1-HRI pathway. *Nature* **579**, 427-432 (2020).

58. Cao, Y., Wang, H., Ouyang, Q. & Tu, Y. The free energy cost of accurate biochemical oscillations. *Nat Phys* **11**, 772-778 (2015).

59. Rath, S.*, et al.* MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations. *Nucleic Acids Res* **49**, D1541-D1547 (2021).

60. Bris, C.*, et al.* Improved detection of mitochondrial DNA instability in mitochondrial genome maintenance disorders. *Genet Med* (2021).

61. Ye, K., Lu, J., Ma, F., Keinan, A. & Gu, Z. Extensive pathogenicity of mitochondrial heteroplasmy in healthy human individuals. *Proc Natl Acad Sci U S A* **111**, 10654-10659 (2014).

62. Klein, H.U.*, et al.* Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer's disease brain. *Mol Neurodegener* **16**, 75 (2021).

63. Tanaka, T.*, et al.* Plasma proteomic signature of age in healthy humans. *Aging Cell* **17**, e12799 (2018).

64. Basisty, N.*, et al.* A proteomic atlas of senescence-associated secretomes for aging biomarker development. *PLoS Biol* **18**, e3000599 (2020).

65. Lehtonen, J.M.*, et al.* FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders. *Neurology* (2016).

66. Sharma, R.*, et al.* Circulating markers of NADH-reductive stress correlate with mitochondrial disease severity. *J Clin Invest* **131**(2021).

67. Lehallier, B.*, et al.* Undulating changes in human plasma proteome profiles across the lifespan. *Nat Med* **25**, 1843-1850 (2019).

68. Pinti, M.*, et al.* Circulating mitochondrial DNA increases with age and is a familiar trait: Implications for "inflamm-aging". *European journal of immunology* **44**, 1552-1562 (2014).

69. Maresca, A.*, et al.* Expanding and validating the biomarkers for mitochondrial diseases. *J Mol Med (Berl)* **98**, 1467-1478 (2020).

70. Gutierrez, J.M.*, et al.* Genome-scale reconstructions of the mammalian secretory pathway predict metabolic costs and limitations of protein secretion. *Nat Commun* **11**, 68 (2020).

71. Goodarzi, H., Elemento, O. & Tavazoie, S. Revealing global regulatory perturbations across human cancers. *Mol Cell* **36**, 900-911 (2009).

72. Hämäläinen, R.H., *et al.* Defects in mtDNA replication challenge nuclear genome stability through nucleotide depletion and provide a unifying mechanism for mouse progerias. *Nature Metabolism* **1**, 958-965 (2019).

73. Wiley, C.D., *et al.* Mitochondrial Dysfunction Induces Senescence with a Distinct Secretory Phenotype. *Cell Metab* **23**, 303-314 (2016).

74. Lozoya, O.A., *et al.* Mitochondrial nicotinamide adenine dinucleotide reduced (NADH) oxidation links the tricarboxylic acid (TCA) cycle with methionine metabolism and nuclear DNA methylation. *PLoS Biol* **16**, e2005707 (2018).

75. Lozoya, O.A., *et al.* Single Nucleotide Resolution Analysis Reveals Pervasive, Long-Lasting DNA Methylation Changes by Developmental Exposure to a Mitochondrial Toxicant. *Cell Rep* **32**, 108131 (2020).

76. Chen, D.P., Lin, Y.C. & Fann, C.S. Methods for identifying differentially methylated regions for sequence- and array-based data. *Brief Funct Genomics* **15**, 485-490 (2016).

77. Oexle, K. & Zwirner, A. Advanced telomere shortening in respiratory chain disorders. *Hum Mol Genet* **6**, 905-908 (1997).

78. Qian, W., *et al.* Chemoptogenetic damage to mitochondria causes rapid telomere dysfunction. *Proc Natl Acad Sci U S A* **116**, 18435-18444 (2019).

79. Horvath, S. & Raj, K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. *Nat Rev Genet* **19**, 371-384 (2018).

80. Higgins-Chen, A.T., *et al.* A computational solution for bolstering reliability of epigenetic clocks: Implications for clinical trials and longitudinal tracking. *bioRxiv*, 2021.2004.2016.440205 (2021).

81. Spendiff, S., *et al.* Mitochondrial DNA deletions in muscle satellite cells: implications for therapies. *Hum Mol Genet* **22**, 4739-4747 (2013).

82. Latorre-Pellicer, A., *et al.* Mitochondrial and nuclear DNA matching shapes metabolism and healthy ageing. *Nature* **535**, 561-565 (2016).

83. Lan, G., Sartori, P., Neumann, S., Sourjik, V. & Tu, Y. The energy-speed-accuracy tradeoff in sensory adaptation. *Nat Phys* **8**, 422-428 (2012).

84. Inak, G., *et al.* Defective metabolic programming impairs early neuronal morphogenesis in neural cultures and an organoid model of Leigh syndrome. *Nat Commun* **12**, 1929 (2021).

85. Jeppesen, T.D., Orngreen, M.C., van Hall, G., Haller, R.G. & Vissing, J. Fat metabolism during exercise in patients with mitochondrial disease. *Arch Neurol* **66**, 365-370 (2009).

86. Saleem, A., *et al.* Polymerase gamma mutator mice rely on increased glycolytic flux for energy production. *Mitochondrion* **21**, 19-26 (2015).

87. Picard, M., *et al.* Mitochondrial functions modulate neuroendocrine, metabolic, inflammatory, and transcriptional responses to acute psychological stress. *Proc Natl Acad Sci U S A* **112**, E6614-6623 (2015).

88. McManus, M.J., *et al.* Mitochondrial DNA Variation Dictates Expressivity and Progression of Nuclear DNA Mutations Causing Cardiomyopathy. *Cell Metab* **29**, 78-90 e75 (2019).

89. Kirkman, M.A., *et al.* Gene-environment interactions in Leber hereditary optic neuropathy. *Brain* **132**, 2317-2326 (2009).

90. Rabenstein, A., *et al.* Smoking and alcohol, health-related quality of life and psychiatric comorbidities in Leber's Hereditary Optic Neuropathy mutation carriers: a prospective cohort study. *Orphanet J Rare Dis* **16**, 127 (2021).

91. Guimier, A., *et al.* PPA2-associated sudden cardiac death: extending the clinical and allelic spectrum in 20 new families. *Genet Med* (2021).

92. Suter, P.M., Schutz, Y. & Jequier, E. The effect of ethanol on fat storage in healthy subjects. *N Engl J Med* **326**, 983-987 (1992).

93. Shelmet, J.J., *et al.* Ethanol causes acute inhibition of carbohydrate, fat, and protein oxidation and insulin resistance. *J Clin Invest* **81**, 1137-1145 (1988).

94. Karan, K.R., *et al.* Mitochondrial respiratory capacity modulates LPS-induced inflammatory signatures in human blood. *Brain Behav Immun Health* **5**(2020).

95. Ganeshan, K., *et al.* Energetic Trade-Offs and Hypometabolic States Promote Disease Tolerance. *Cell* **177**, 399-413 e312 (2019).

96. Taivassalo, T., *et al.* The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. *Brain* **126**, 413-423 (2003).

97. Bates, M.G., *et al.* Defining cardiac adaptations and safety of endurance training in patients with m.3243A>G-related mitochondrial disease. *Int J Cardiol* **168**, 3599-3608 (2013).

98. Newman, J., *et al.* Preliminary Evaluation of Clinician Rated Outcome Measures in Mitochondrial Disease. *J Neuromuscul Dis* **2**, 151-155 (2015).

99. Galna, B., *et al.* Discrete gait characteristics are associated with m.3243A>G and m.8344A>G variants of mitochondrial disease and its pathological consequences. *J Neurol* **261**, 73-82 (2014).

100. Strauss, K.A., *et al.* Severity of cardiomyopathy associated with adenine nucleotide translocator-1 deficiency correlates with mtDNA haplogroup. *Proc Natl Acad Sci U S A* **110**, 3453-3458 (2013).

101. Delaney, N.F., *et al.* Metabolic profiles of exercise in patients with McArdle disease or mitochondrial myopathy. *Proc Natl Acad Sci U S A* **114**, 8402-8407 (2017).

102. Jeppesen, T.D., Orngreen, M.C., Van Hall, G. & Vissing, J. Lactate metabolism during exercise in patients with mitochondrial myopathy. *Neuromuscul Disord* **23**, 629-636 (2013).

103. Heinicke, K., *et al.* Exertional dyspnea in mitochondrial myopathy: clinical features and physiological mechanisms. *Am J Physiol Regul Integr Comp Physiol* **301**, R873-884 (2011).

104. Grassi, B., *et al.* Metabolic myopathies: functional evaluation by analysis of oxygen uptake kinetics. *Med Sci Sports Exerc* **41**, 2120-2127 (2009).

105. Grassi, B., *et al.* Impaired oxygen extraction in metabolic myopathies: detection and quantification by near-infrared spectroscopy. *Muscle Nerve* **35**, 510-520 (2007).

106. Eom, S., *et al.* Cause of Death in Children With Mitochondrial Diseases. *Pediatr Neurol* **66**, 82-88 (2017).

107. Picard, M., *et al.* Mitochondrial dysfunction and lipid accumulation in the human diaphragm during mechanical ventilation. *Am J Respir Crit Care Med* **186**, 1140-1149 (2012).

108. Krishnan, K.J., Bender, A., Taylor, R.W. & Turnbull, D.M. A multiplex real-time PCR method to detect and quantify mitochondrial DNA deletions in individual cells. *Anal Biochem* **370**, 127-129 (2007).

109. Sturm, G., *et al.* A Multi-Omics and Bioenergetics Longitudinal Aging Dataset in Primary Human Fibroblasts with Mitochondrial Perturbations. *bioRxiv*, 2021.2011.2012.468448 (2021).

110. Parrinello, S., *et al.* Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. *Nat Cell Biol* **5**, 741-747 (2003).

111. Jain, I.H., *et al.* Hypoxia as a therapy for mitochondrial disease. *Science* **352**, 54-61 (2016).

112. Ware, S.A., *et al.* An automated, high-throughput methodology optimized for quantitative cell-free mitochondrial and nuclear DNA isolation from plasma. *J Biol Chem* **295**, 15677-15691 (2020).

113. Belmonte, F.R., *et al.* Digital PCR methods improve detection sensitivity and measurement precision of low abundance mtDNA deletions. *Scientific reports* **6**, 25186 (2016).

114. Bray, N.L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. *Nat Biotechnol* **34**, 525-527 (2016).

115. Ge, S.X., Jung, D. & Yao, R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. *Bioinformatics* **36**, 2628-2629 (2020).

116. Cawthon, R.M. Telomere measurement by quantitative PCR. *Nucleic Acids Res* **30**, e47 (2002).

117. Lin, J., *et al.* Analyses and comparisons of telomerase activity and telomere length in human T and B cells: insights for epidemiology of telomere maintenance. *Journal of immunological methods* **352**, 71-80 (2010).

Cohort #	Author (year)	N= (W/M)	Age	Genetics	Mutations	Clinical
Cohort 1	Taivassalo (2003)	40 Mito (22/18) 32 Ctrl (9/22)	37 39	mtDNA (n=35) nDNA (n=5)	m.3242A>G, m.8344A>G, m.14710G>A, m.5543T>C, m.4409T>C, m.14846G>A, m.5920G>A, *ND2* and *COXIII* microdeletions, sDel, mDel, other (3), unknown (4)	CPEO, MELAS, MERRF, EI, mixed
Cohort 2	**5a**:Bates (2013) **5b**:Newman (2015) **5c**:Galna (2014) **5d**:Unpublished	a:10 Mito (4/6) 10 Ctrl (4/6) b:8 Mito (5/3) c:6 Mito (1/5) d:8 Mito (2/6)	42.4 39.0 42 40.5 42	mtDNA	5a:m.3243A>G 5b:m.3243A>G 5c:m.8344A>G + 3243A>G 5d:sDel	SNHL, DM, Ei, AT, FT, DP, mixed
Cohort 3	Strauss (2013)	9 Mito (7/2) 28 Ctrl	14.6 14.0	nDNA	SLC25A4 (*ANT1*) mutations (c.523delC, p.Q175RfsX38)	CM, EI, insomnia, DP, anxiety
Cohort 4	Delaney (2017)	21 Mito (15/6) 12 Ctrl (8/4)	44 34	mtDNA	sDel, mDel, m.3243A>G, m.10010T>C, m.12261T>C, ISCU, m.4281A>G, *CYTB*, m.8344A>G, m.5543T>C	Mild to severe mixed
Cohort 5	MiSBIE (unpublished)	23 Ctrl (15/8) 12 Mito (8/4)	34.0 32.9	mtDNA	m.3243A>G	MELAS, mixed
Cohort 6	Jeppesen (2013)	10 Mito (6/4) 10 Ctrl (6/4)	39 39	mtDNA	m.3243A>G, 8344A>T, 4409T>C, 8340G>A, 2-bp deletion, 12,113–14422, 7177–13767	CPEO, EI, HI, GI, Enc, SS, DM, ME, AT
Cohort 7	Jeppesen (2009)	10 Mito (5/5) 10 Ctrl (5/5)	39 40	mtDNA	m.3243A>G, m.8344A>T, m.5543t>C, sDel	CPEO, EI, HI, GI, Enc, SS, DM, ME, AT
Cohort 8	Heinicke (2011)	5 Mito (2/3) 4 Ctrl (2/2)	42 34	mtDNA nDNA	m.3243A>G, m.5543T>C, m.14846G>A, ISCU	Myopathy
Cohort 9	Grassi (2009)	15 Mito (7/8) 21 PCtrl[2] (7/14) 22 Ctrl (9/13)	40.1 38.3 37.9	mtDNA	sDel, mDel, m.8344A>G	Myopathy
Cohort 10	Porcelli (2016)	6 Mito (2/4)	51	mtDNA	mDel, sDel, m.3255G>A, m.3243A>G	Myopathy
Cohort 11	Grassi (2007)	6 Mito (1/5) 25 PCtrl[2] (5/20) 20 Ctrl (8/12)	37.8 31.6 32.7	mtDNA	mDel, m.8344A>G	Myopathy
Cohort 12	Hou (2019)	89 Mito (57/32)	30.4	mtDNA nDNA	sDel, POLG, RRM2B, Twinkle, TK2, m.3243A>G, m.8344A>G, m.5541C>T, m.10158C>T	MELAS, CPEO
Cohort 13	Kaufman (2011)	31 Mito (16/15) 54 Ctrl[1] (15/39)	30 38	mtDNA	m.3243A>G	MELAS
Cohort 14	Barends (2015)	30 Mito (15/15)	50.4[3]	mtDNA nDNA	m.3243A>G, sDel, mDel, c.1635C>G, m.8344A>G, m.13094T>C, m.14709T>C, m.5816A>G, m.14484T>C, m.12258G>A, *POLG* mutations	MELAS, CPEO, KSS, MERRF, mixed
Cohort 15	Eom (2017)	221 Mito *Pediatric*	6.0[3]	mtDNA nDNA	m.3243A>G, LS mutations	LS, MELAS, mixed
Cohort 16	Wedatilake (2013)	44 Mito (20/24) *Pediatric*	<14[3]	nDNA	*SURF1* mutations	Poor feeding/vomiting, PWG, DD, HT, MD, AT
Cohort 17	Newcastle cohort (unpublished)	109 Mito (56/53)	48.1	nDNA, mtDNA	In addition to Cohort 14: *AGK, ETFDH*, m.10010T>C, m.11778G>A, m.13513G>A, m.8993T>C, m.8993T>G, m.9176T>C, m.9997T>C, *MRPL44, NDUFAF6*, *NDUFS1*, *RRM2B*, *SDHA*, *SURF1*, *TYMP*	MELAS, PMM, MERRF, MIDD, MNGIE, KSS, CM, mixed

Table 1. Human cohorts included in the quantitative meta-analysis of energy expenditure and related clinical phenotypes in patients with mitochondrial diseases (Figure 1). *Abbreviations: ANT1*: adenine nucleotide translocator 1; *AT*: ataxia; *CM*: cardiomyopathy; *CPEO*: chronic progressive external ophthalmoplegia*; DD:* developmental delay; *Dm*: diabetes mellitus*; DP*: depression; *EI*: pure exercise intolerance; *Enc*: encephalopathy; *FT*: fatigue; *GI*: glucose intolerance*; HI*: hearing impairment; *HT:* hypotonia; *KSS*: Kearns-Sayre Syndrome; *LS:* Leigh Syndrome; *MD:* movement disorder; *mDel*: multiple mtDNA deletions; *ME*: myoclonic epilepsy*; MELAS*: mitochondrial encephalopathy, lactic acidosis, stroke-like episodes; *MERRF*: myoclonus epilepsy with ragged red fibres; *MiSBIE*: Mitochondrial Stress, Brain Imaging, and Epigenetics study*; mtDNA*: mitochondrial DNA*; nDNA*: nuclear DNA; *PWG:* poor weight gain; *sDel*: single, large-scale mtDNA deletion; *SNHL*: sensorineural hearing loss; *SS*: short stature. [1]: controls were m.3243A>G carrier relatives without MELAS. [2]: PCtrl: “patient controls” with symptoms of mitochondrial myopathy but with negative biopsy. [3]: based on age at death. Number of women (W) and men (M) are shown in parentheses.

SUPPLEMENTAL MATERIAL

Supplemental File 1. Table of differentially expressed genes for SURF1 cells over 0 to 75 days of growth.

Supplemental File 2. Table of differentially expressed genes for Oligo cells over 35 to 110 days of growth.

Supplemental File 3. Table of differentially expressed genes shared across SURF1 and Oligo cells.

Supplemental File 4. Gene expression heatmaps of select pathways in control, SURF1, and Oligo cells.

Supplemental File 5. Differentially methylated CpGs for SURF1 cells over 0 to 75 days of growth.

Supplemental File 6. Differentially methylated CpGs for Oligo cells over 35 to 110 days of growth.

Supplemental File 7. Differentially methylated CpGs shared across SURF1 and Oligo cells.

Supplemental File 8. Differentially methylated regions for SURF1 cells over 0 to 75 days of growth.

Supplemental File 9. Differentially methylated regions for Oligo cells over 35 to 110 days of growth.

Supplemental File 10. Differentially methylated regions shared in both SURF1 and Oligo cells.



Extended Data Figure 1. Physiological profiles of mitochondrial disease in Cohort 2 by genetic diagnosis. (**A**) Resting heart rate (HR, $P<0.05$), (B) resting whole body oxygen consumption (VO_2, $P<0.001$), and (**C**) body mass index (BMI, $P=0.061$) in 4 different groups with mtDNA defects. Controls and m.3243A>G (1) groups are described in Bates et al. (2013), m.3243A>G (2) in Newman et al. (2015), m.8344A>G in Galna et al. 2013, and sDel is an unpublished cohort from the same laboratory. Data are means ± SEM. P values from Brown-Forsythe ANOVA.



Extended Data Figure 2. Bioenergetic profiling of SURF1-disease cells. (**A**) Conversion of OCR and ECAR values into ATP production rates (J_{ATP}, pmol ATP per minute) (**B**) Lifespan trajectories of $J_{ATPtotal}$ at maximal uncoupling (FCCP injection) across the SURF1 lifespan (up to 150 days). Percentages show the total average difference between SURF1 and Control. (**C**) Spare capacity for respiration (left) and glycolysis (right), measured as the difference between maximal uncoupled to baseline values. (**D**) Lifespan trajectories of non-mitchondrial respiration after shutdown of the ETC (R+A injection) across the SURF1 lifespan (up to 150 days). n = 3 individuals per group, 7-9 timepoints per individual. Data are means ± SEM., * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, unpaired t-test.



Extended Data Figure 3. Glucose dependency of SURF1-mutant cells. (**A**) Brightfield images of human fibroblasts from Donor 2 (left panel) and Patient 2 (right panel) cultured under different glucose conditions for 6 days: high glucose (25mM), low/normal glucose (5.5 mM), and no glucose (0 mM). After 5 days, fibroblasts from Patient3 display massive cell death when cultured without glucose (i), suggesting increased glucose dependency. (**B**) Glucose dependency test with sequential injections of glucose, oligomycin, and 2-deoxyglucose on a single healthy control (Donor 2) and SURF1-disease (Patient 2) fibroblasts cell line after overnight treatment in (i) 25 mM Glucose, (ii) 5.5 mM Glucose, or (iii) 0 mM Glucose. (**C**) ECAR measured before (-) and after (+) glucose injection across three independent experiments on the same control and SURF1 cell lines in different glucose conditions as shown in and (B). SURF1 cells show a more rapid increase in ECAR following glucose injection compared to control cells, highlighting their propensity to oxidize glucose. Statistical test performed using Šídák's multiple comparisons test on a two-way anova. (**D**) ECAR measured after 2DG injection across three independent experiments on the same control and SURF1 cell lines in different glucose conditions as shown in and (B). Data are means ± SEM. * $P < 0.05$, ** $P < 0.01$.



Extended Data Figure 4. Mitochondrial defects show altered rates of cytological aging. (**A**) Timecourse of cell volume across cellular lifespan. (**B**) Rate of volume loss for each cell line. Rates are determined using a linear slope. (**C**) Hayflick limit compared to initial cell volume of each line for Control, SURF1-disease, and Oligo-treated cells. (**D**) Timecourse of cell death across cellular lifespan. (**E**) Maximum percentage of dead cells for each cell line.



Extended Data Figure 5. Cellular morphological oscillations of oligomycin-treated fibroblasts (**A**) Titration of oligomycin on basal OCR and ECAR measures (n=20-23 technical replicates, error-bars=SEM) in Donor 5. Arrows show the selected concentration for chronic treatment (1nM) which induces a 86% decrease in OCR and elevate ECAR by 257%, reflecting a robust metabolic recalibration in response to ATP synthesis from OxPhos. (**B**) Timecourses of the percent of dead cells at each passage across the cellular lifespan. Measurements were taken at each passage using trypan blue. (**C**) Bright-field imaging of control (left) and 1nM oligo-treated cells (right) using a 20x magnification. (**D**) Timecourse of morphological classification across the cellular lifespan. Cells were crudely characterized as either normal or 'network-like' at each passage by eye. (**E**) Networked oligo-treated cells show robust shift in the transcriptional space in principled component analysis. (**F**) Rescue experiment using a combination of 1nM oligo and 100nM dexamethasone (DEX). (**G**) Bright-field imaging of oligo-treated cells (top-panel) and a combination of oligo and dexamethasone (bottom-panel). Oligo+DEX cells show no signs of network morphology. Treatment conditions for healthy controls include chronic addition of 1nM oligomycin (Sigma-Aldrich #75351), 100nM dexamethasone (DEX, Sigma-Aldrich #D4902) and a combination of 1nM oligomycin and 100nM DEX.



Extended Data Figure 6. Circos plots depicting the time course of mtDNA deletions in Control and SURF1 fibroblasts. Each circos plot depicts mitochondrial genome annotations (outer circle), percentage of deletions (gray gradient), depth of base coverage (blue area), soft-clipping BLASTn links (red arcs) and percent heteroplasmy (intensity of red arcs) [REF: Goudenège et al. 2019] (**A**) mtDNA deletion time-course of a control fibroblast from a healthy donor. (**B**) mtDNA deletion time-course of a patient fibroblast with SURF1 mutation. (**C**) mtDNA deletion time-course of a healthy fibroblast treated with 1nM Oligomycin-treated cells. N/A indicates data not available for given timepoint.



Extended Data Figure 7. Length distribution of mtDNA deletion fragments days in culture. (**A**) Frequency distribution of mtDNA deletions and length of deletion in three healthy donors across time. (**B**) High deletion frequency and length distribution of mtDNA fragments in three patients with SURF1 mutation, and (**C**) in Oligo-treated cells. (**D**) Mitochondrial mutation count in control, SURF1-mutant, and Oligo-treated fibroblasts at 1-5% and greater than 5% heteroplasmy. (**E**) Mean and (**F**) max mtDNA heteroplasmy levels across the cellular lifespan. We note that our longitudinal analysis demonstrated the spontaneous occurrence of a m.3243A>G mutation in the Oligo-treated cells of Donor2, which appeared at passage 22 and persisted at all timepoints until passage 34 (time elapsed = 86 days). Data are mean ± SEM.* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, mixed effects model (fixed affect of clinical condition and days grown, random effects of cell line).



Extended Data Figure 8. Cell-free molecules. (**A-B**) Cell-free nuclear DNA dynamics using qrt-PCR, normalized to the number of cells at time of sampling, across the cellular lifespan trajectories (**A**) and averages (**B**). (**C-D**) Cell-free mitochondrial DNA per nuclear DNA across the cellular lifespan trajectories (**C**) and averages (**D**). Data are mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, mixed effects model (fixed effect of clinical condition and days grown, random effects of cell line).



Extended Data Figure 9. Ribosomal gene expression. (**A**) Heatmap of ribosomal gene expression. Ribosomal genes were selected from the KEGG database (https://www.genome.jp/kegg/pathway/hsa/hsa03010.html). Values are derived from normalized expression centered to the median of the youngest control timepoints. (**B**) Barplot of ribosomal gene expression between control, SURF1-mutant, and oligo-treated timepoints. Each datapoint is the median normalized expression across all ribosomal subunit genes. Data are mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, mixed effects model (fixed affect of clinical condition and days grown, random effects of cell line).



Extended Data Figure 10. Transcriptomic Remodeling. (**A**) Volcano plots of differential expressed genes (DEGs) for LMER model of SURF1-mutant fibroblasts (top-panel) and Oligo-treated fibroblasts (bottom-panel). (**B**) Timecourse of top 3 up- and down-regulated DEGs in both SURF1-disease and Oligo-treated fibroblasts.



Extended Data Figure 11. mtDNA gene expression of coding genes and tRNAs. Circular mtDNA map with its 37 genes annotated. Graphs show normalized expression values (log2 fold-change relative to median of control replicates) for control, SURF1 mutant donors, and Oligo-treated healthy donors. Each point represents the median of all timepoints for a given cell line (35to150 days). The inner ring induces all transfer RNAs (tRNAs); the outer ring includes ribosomal and messenger RNA (rRNA and mRNA) genes.



Extended Data Figure 12. DNAmAge clocks. (**A**) Rate of epigenetic aging using original DNAmAge clocks for control, SURF1, and oligo-treated cells per population doubling. (**B**) Average rate of epigenetic aging across all original clocks. Each datapoint represents a different clock. (**C-D**) Epigenetic age across replicative lifespan calculated using original epigenetic clocks (C) and PC-based clocks (D). Values are baselined to youngest timepoint of each cell group. (**E-F**) Rate of epigenetic aging for control, SURF1, and oligo-treated cells per year grown for (**E**) PC-based and (**F**) original DNAmAge clocks. Rates are defined as the linear rate between 25-75 days (3-4 timepoints/cell line). Significance values were calculated using a multiple comparison two-way anova. Data are means ± SEM. * P < 0.05, ** P < 0.01.